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ANTIBODES DIRECTED TOWARD THE 
HIV-1 GP120 CD4 BINDING STE WITH 
INCREASED POTENCY AND BREADTH 
CROSS-REFERENCE TO RELATED 
APPLICATION(S) 
The present application claims priority to and the benefit 
of U.S. Provisional Application Ser. No. 61/570,173 filed on 
Dec. 13, 2011, and is continuation in part of U.S. patent 
application Ser. No. 13/558.312, filed Jul. 25, 2012, the 
entire contents of both of which are incorporated herein by 
reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with government Support under 
P01 A1081677-01, awarded by the National Institutes of 
Health. The government has certain rights in the invention. 
INCORPORATION BY REFERENCE 
The present application contains a Sequence Listing 
which has been submitted in ASCII format via EFS-Web and 
is hereby incorporated by reference in its entirety. Said 
ASCII copy, created on Jul. 25, 2012, is named 
1358312SEQLISTING..txt, created Jul. 25, 2012 and being 
47.972 bytes in size. 
TECHNICAL FIELD 
This application is directed to a gp120 anti-CD4 binding 
site (anti-CD4bs) antibody composition that has improved 
potency and breadth against the human immunodeficiency 
virus, (HIV) which causes acquired immunodeficiency syn 
drome (AIDS). 
TECHNICAL BACKGROUND 
Three decades after the emergence of HIV there is still no 
vaccine, and AIDS remains a threat to global public health. 
However, some HIV-infected individuals eventually develop 
broadly neutralizing antibodies (bNAbs), i.e., antibodies that 
neutralize a large panel of HIV viruses and that can delay 
viral rebound in HIV patients. Such antibodies are relevant 
to vaccine development, as evidenced by the prevention of 
infection observed after passive transfer to macaques. Anti 
bodies obtained by recent methods target several epitopes on 
the viral spike gp120 protein. These antibodies show broad 
and potent activity, and are referred to as highly active 
agonistic anti-CD4 binding site antibodies (HAADs). 
HAADS mimic binding of the host receptor CD4 protein by 
exposing the co-receptor binding site on gp120. Despite 
isolation from different donors, HAADs are derived from 
two closely-related Ig V, genes that share gp120 contact 
residues (Sheid et al., 2011, Science, 333:1633-1637 and 
Zhou et al.: Science, 2010, 329: 811-817). 
Structural analysis of gp120 complexed with VR001 (a 
highly potent and broad HAAD), and gp120 complexed with 
each of VRC03 and VRC-PG04, (two new CD4bs antibod 
ies sharing the VRCO1 germline V gene) revealed conver 
gence of gp120 recognition despite low sequence identities 
(48-57% in V: 62-65% in V.) (Wu et al: 2011, Science, 
333:1593-1602). However; sequence differences between 
these clonally-unrelated anti-CD4 antibodies make it diffi 
cult to determine the structural features that yield neutral 
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2 
ization potency and breadth to thereby obtain a potent HIV 
antibody that is effective across many 111V strains. 
SUMMARY 
In some embodiments of the present invention, a compo 
sition includes an isolated anti-CD4 binding site (anti 
CD4bs) potent VRC01-like (PVL) antibody having a heavy 
chain and a light chain. The heavy chain of the anti-CD4bs 
PVL antibody includes a heavy chain substitution at a 
position equivalent to Phe-A3 of a CD4 receptor protein. The 
heavy chain substitution is selected from hydrophobic amino 
acids, glycine, histidine, arginine, glutamine, asparagine, 
lysine, glutamic acid, and aspartic acid. In some embodi 
ments, for example, the heavy chain Substitution is trypto 
phan, tyrosine, phenylalanine, glycine, histidine, arginine, 
glutamine, or asparagine. 
According to Some embodiments of the present invention, 
the anti-CD4bs PVL, antibody also includes a light chain 
substitution of tyrosine for serine at position 28 of the light 
chain. The light chain may be selected from SEQ NOs: 1, 3, 
5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33,35, 37, 
39, 41, and 43. 
The position equivalent to Phe-A3 of the CD4 receptor 
protein may be position 54 of the heavy chain. Also, the 
heavy chain may be selected from SEQ ID NOS: 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 
42, 44, 45, and 46. 
The anti-CD4bs PVL antibody may be selected from 
VRC01, VRCO2, NIH-45-46, 3BNC60, 3BNC117, 
3BNC62, 3BNC95, 3BNC176, 12A21, VRC-PG04, VRC 
CH30, VRC-CH31, VRC-CH32, VRC-CH33, VRC-CH34, 
VRC03 heavy chain with VRC01 light chain, gVRC-H5 
(d74) heavy chain with VC-PG04 light chain, gVRC-H12 
(d74) heavy chain with VRC-PG04 light chain, VRC03, 
VRC01 heavy chain with VRC03 light chain, 3BNC55, 
3BNC91, 3BNC104, 3BNC89, 12A21, and VRC-PC104b. 
In some embodiments, for example, the anti-CD4bs PVL 
antibody may be NIH45-46. 
According to Some embodiments of the present invention, 
a nucleic acid molecule encodes the heavy chain and the 
light chain of the anti-CD4bs PVL antibody. The heavy 
chain of the anti-CD4bs PVL antibody encoded by the 
nucleic acid molecule includes a heavy chain Substitution at 
a position equivalent to Phe-A3 of a CD4 receptor protein. 
The heavy chain substitution is selected from hydrophobic 
amino acids, glycine, histidine, arginine, glutamine, aspara 
gine, lysine, glutamic acid, and aspartic acid. In some 
embodiments, for example, the heavy chain Substitution is 
tryptophan, tyrosine, phenylalanine, glycine, histidine, argi 
nine, glutamine, or asparagine. 
In some embodiments, the light chain of the anti-CD4bs 
PVL antibody encoded by the nucleic acid molecule 
includes a light chain substitution of serine at position 28 of 
the light chain with tyrosine. 
In some embodiments, a vector includes the nucleic acid 
molecule. In other embodiments, a cell includes the vector. 
According to Some embodiments of the present invention, 
a pharmaceutical composition includes the composition 
including the isolated anti-CD4bs PVL antibody, or a frag 
ment thereof. The pharmaceutical composition further 
includes a pharmaceutically acceptable carrier. The anti 
CD4bs PVL antibody has a heavy chain and a light chain. 
The heavy chain of the anti-CD4bs PVL antibody includes 
a heavy chain substitution at a position equivalent to Phe-A3 
of a CD4 receptor protein. The heavy chain substitution is 
selected from hydrophobic amino acids, glycine, histidine, 
US 9,493,549 B2 
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arginine, glutamine, asparagine, lysine, glutamic acid, and 
aspartic acid. In some embodiments, for example, the heavy 
chain Substitution is tryptophan, tyrosine, phenylalanine, 
glycine, histidine, arginine, glutamine, or asparagine. The 
anti-CD4bs PVL antibody may also include a light chain 
substitution of tyrosine for serine at position 28 of the light 
chain. 
In some embodiments of the present invention, a method 
of preventing or treating an HIV infection oran HIV-related 
disease includes administering a therapeutically effective 
amount of a composition including the anti-CD4bs PVL 
antibody having the heavy chain substitution. The anti 
CD4bs PVL antibody may further include a light chain 
substitution of the serine at position 28 of the light chain 
with tyrosine. 
According to other embodiments of the present invention, 
a method of increasing potency and breadth of an isolated 
anti-CD4bs PVL antibody having a heavy chain and a light 
chain includes identifying a target amino acid on the heavy 
chain that is at a position equivalent to Phe43 of a CD4 
receptor protein, and Substituting the target amino acid with 
a heavy chain substitution selected from hydrophobic amino 
acids, glycine, histidine, arginine, glutamine, asparagine, 
lysine, glutamic acid and aspartic acid. For example, the 
heavy chain Substitution ma include phenylalanine, trypto 
phan, tyrosine, glycine, histidine, arginine, glutamine or 
asparagine. The position equivalent to Phe-A3 of the CD4 
receptor protein may be position 54 of the heavy chain. The 
method may further include substituting serine at position 28 
of the light chain with tyrosine. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawings will be provided by the 
Office upon request and payment of the necessary fee. 
These and other features and advantages of the present 
invention will be better understood by reference to the 
following detailed description when considered in conjunc 
tion with the accompanying drawings. 
FIG. 1A is a superimposition of a structural depiction of 
NIH45-46 Fab alone (in blue) and of NIH45-46-gp120 
complex (in magenta), according to embodiments of the 
present invention. 
FIG. 1B is a structural depiction of NIH45-46-gp120 
(93TH053) complex and the binding interface and domains 
labeled and colored as indicated, with NIH45-46 Fab shown 
in magenta (heavy chain) and light purple (light chain), and 
gp120 shown in yellow (inner domain) and grey (outer 
domain), according to embodiments of the present inven 
tion. 
FIG. 2 is a table of the data and refinement statistics from 
the X-ray diffraction data collected from the NIH45-46 Fab 
crystal structure and the NIH45-46-gp120 (93TH-057) com 
plex as depicted in FIGS. 1A and 1B, according to embodi 
ments of the present invention. 
FIG. 3A is a sequence alignment of the heavy chain 
variable (V) domains of NIH45-46 (SEQ ID NO: 6) and 
VRC01 (SEQ ID NO: 2) antibodies, in which the open 
circles indicate NIH45-46 side chain residues that contact 
gp120 and closed circles indicate NIH45-46 main-chain, or 
main-chain and side chain residues that contact gp120, 
according to embodiments of the present invention. 
FIG. 3B is a sequence alignment of the light chain 
variable (V) domains of NIH45-46 (SEQ ID NO. 5) and 
VRC01 (SEQ ID NO: 1) antibodies, in which the open 
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4 
circles indicate NIH45-46 side chain residues that contact 
gp120 and closed circles indicate NIH45-46 main-chain, or 
main-chain and side chain residues that contact gp120, 
according to embodiments of the present invention. 
FIG. 4A is a Superimposition and comparison of a struc 
tural depiction of NIH45-46-gp120 complex (shown in 
magenta) and a structural depiction of VRCO1-gp120 com 
plex (shown in blue), according to embodiments of the 
present invention. 
FIG. 4B is close-up view of the conserved interactions in 
the gp120 contacts of NIH45-46 and VRC01, with the CD4 
binding loop of gp120 labeled and shown in yellow, accord 
ing to embodiments of the present invention. 
FIG. 5 is a depiction of the interactions of NIH45-46 
gp120 complex and VRC01-gp120 complex with NIH45-46 
shown in magenta, VRCO1 in blue, and domains of gp120 
shown as follows: outer domain (yellow), bridging sheet 
(orange), CD4 binding loop (blue), V5 loop and D Loop 
(green), and inner domain (grey); with the contact region 
between CDRH3 insertion residues of NIH45-46 and gp120 
shown in the close-up box with insertion residues 99a-99b 
labeled alphabetically, according to embodiments of the 
present invention. 
FIG. 6A is a structural depiction of the binding interface 
of a NIH45-46-gp120 complex characterized by the direct 
hydrogen bond (dotted line) between the main-chain atom of 
Gly54v4s-46 (magenta) and Asp368 120 (gray) and two 
water molecules (larger spheres in dotted line), according to 
aspects of the present invention. 
FIG. 6B is a structural depiction of the contact interface 
of a CD4-gp120 complex, characterized by CD4 (yellow) 
forming two direct hydrogen bonds (dotted lines) with the 
CD4-binding loop on gp120, according to embodiments of 
the present invention. 
FIG. 6C is a structural depiction of the contact interface 
of a VRC03-gp120 complex, characterized by a carbonyl 
oxygen of Trp54 forming a hydrogen bond with 
Asp36820, according to embodiments of the present 
invention. 
FIG. 7 is a structural depiction of the binding interface of 
a NIH45-46-gp120 complex, as shown by a hydrogen bond 
network between the main-chain carbonyl oxygen of 
Ala281120, Tyr99dvas-as in CDRH-3, and Lyss2Mt,45-46 
in CDRH2, in which yellow dots represent hydrogen bonds, 
and as shown in the inset box: a sulfate ion (yellow) 
substitutes for Ala2812 the unbound NIH45-46, accord 
ing to embodiments of the present invention. 
FIG. 8 is a structural depiction of the binding interface of 
a NIH45-46-gp120 complex, as shown by the electrostatic 
interactions between Asp99cvitas as and Lys9712o (lower 
left dotted line) and hydrogen bonds between 
Asp99cvmas-as-Tyr)74s-46 (upper left dotted line) and 
Arg99bviras-as-ASn99,120 (lower right dotted line), 
according to embodiments of the present invention. 
FIG. 9A is a structural depiction of NIH45-46-gp120 
complex (with NIH45-46 shown in magenta and gp120 
shown in grey) Superimposed with a structural depiction of 
CD4-gp120 complex (with CD4 shown in yellow and gp120 
shown in orange), with an arrow and label of Phe-A3 of CD4. 
according to embodiments of the present invention. 
FIG.9B is a close-up view of the superimposition of FIG. 
9A with the CDRH2 loop of NIH45-46 (magenta) and the 
CDR2-like loop of CD4 (yellow) interacting with gp120 
(grey Surface), according to embodiments of the present 
invention. 
FIG. 9C is a structural depiction of a CD4-gp120 
(ZM135M.PL10a) complex with the contact interface 
US 9,493,549 B2 
5 
labeled and colored as in FIG. 1B, and the initial site of CD4 
attachment is indicated with the oval, according to embodi 
ments of the present invention. 
FIG. 9D is a structural depiction of a NIH45-46-gp120 
(93TH057) complex with the contact interface labeled and 
colored as in FIG. 1B, and the corresponding Phe-A3, 
cavity as shown in FIG. 9B is indicated by the asterisk, 
according to embodiments of the present invention. 
FIG. 9E is a structural depiction of a VRC01-gp120 
5 
(93TH057) complex with the contact interface labeled and 10 
colored as in FIG. 1B, according to embodiments of the 
present invention. 
FIG. 10A is a structural depiction of a NIH45-46-gp120 
complex superimposed with a VRC01-gp120 complex, in 
which the Tyr74 shows different interactions with gp120, 
and the gp120 bridging sheet is depicted with the broad 
arrows in gp120 and the asterisks indicate a recombinant 
Gly linker, according to embodiments of the present inven 
tion. 
FIG. 10B is a close-up view of the structural depiction of 
FIG. 10A showing the hydrogen bond between 
Tyr74 as and the main-chain carbonyl oxygen of 
Leu12220, according to embodiments of the present 
invention. 
FIG. 11A is a stereo view of a structural depiction of a 
NIH45-46-gp120 complex superimposed with a VRC01 
gp120 complex showing that Tyr28to interacts with an 
N-linked carbohydrate attached to Asn276 and the side 
chain counterpart residue Ser28s in the NIH45-46 
complex faces away from gp120 to hydrogen bond with 
Arg64 as a (the arrowheads point to CC. atoms of 
residue 28 in each structure), according to embodiments of 
the present invention. 
FIG. 11B is a superimposition of NIH45-46LC bound to 
gp120 (magenta) and unbound (green) showing the hydro 
gen bonds between Ser28 and Arg64, according to embodi 
ments of the present invention. 
FIG. 12 is a structural depiction of gp12 and highlighted 
differences in the gp1.20 resurfaced stabilized core 3 (RSC3) 
variant, in which the NIH45-46 contact surfaces are shown 
and the RSC3 mutations shown, with labeling and coloring 
as in FIG. 1B, according to embodiments of the present 
invention. 
FIG. 13A shows sensorgrams from Surface plasmon reso 
nance (SPR) experiments of binding experiments of the 
93TH057 gp120 protein with NIH45-46 and NIH45-46'' 
Fabs, as indicated, and a table of the K values is shown, 
according to embodiments of the present invention. 
FIG. 13B shows sensorgrams from surface plasmon reso 
nance (SPR) experiments of binding experiments of the 
CAP244.2.00 D3 gp120 protein with NIH45-46 and NIH45 
46'' Fabs, as indicated, and a table of the K values is 
shown, according to embodiments of the present invention. 
FIG. 13C shows sensorgrams from surface plasmon reso 
nance (SPR) experiments of binding experiments of the 
Q259.d2.17 gp120 protein with NIH45-46 and NIH45 
46'' Fabs, as indicated, and a table of the K values is 
shown, according to embodiments of the present invention. 
FIG. 14 shows neutralization curves for NIH45-46'' 
and NIH45-46 in strains DU172.17 and TRO. 11, as indi 
cated, according to embodiments of the present invention. 
FIG. 15A shows a schematic comparing neutralization 
potencies of NIH45-46, NIH45-46'', NIH45-46, and 
NIH45-46, with ICs values for each color-coded as 
shown, according embodiments of the present invention. 
FIG. 15B shows a graphical comparison of neutralization 
coverage and potency for VRC01.. Monogram (Monogram is 
a panel of 162 viral strains), VRC01 CAVD (CAVD is a 
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panel of 118 viral strains), PGT121 Monogram, PGT128 
Monogram, NIH45-46 CAVD, NIH45-46 hard panel (See 
Tables 7 and 8), and NIH45-46G54W hard panel, according 
to embodiments of the present invention. 
FIG. 15C shows neutralization summary spider graphs 
comparing ICso values for VRC01. NIH45-46, and NIH45 
46'' for 65 common viruses, in which each color repre 
sents a different HIV clade, the length of the lines and size 
of circles are inversely proportional to the ICso value, the 
distance between the outer and the inner circle and the 
distance from the inner circle to the center of a spider graph 
each span two natural logs in ICso concentration, the dots on 
the outer circle indicate strains with ICso values less than 
0.018 ug/ml whose lines were truncated in the graph, and the 
size of each dot is inversely proportional to the ICso value, 
according to embodiments of the present invention. 
FIG. 16 is a schematic illustration of, on the left: antibody 
interactions (magenta and blue-gray) made with gp120 
(black); and on the right: CD4 (magenta) with gp120 
(black), with the viewpoint of the diagram shown in the inset 
box, according to embodiments of the present invention. 
FIG. 17 is a graph of a neutralization assay showing the 
effects of mutations at critical residues in YU2 gp120 on 
neutralization by PVL antibody NIH45-46'' in which the 
ICso values are the mean of several independent experi 
ments, and the graph shows one experiment, according to 
embodiments of the present invention. 
FIG. 18 is a graph of the breadth of neutralization (% 
COVERAGE) against a cross-clade panel of 118 primary 
HIV isolates as a function of ICso cut off (ug/ml), accord 
ing to embodiments of the present invention. 
FIG. 19 is a graph showing the neutralization of VC100 
clones shown as the log of the ICs values (ug/ml) for each 
of VRC01 antibody, NIH45-46'' antibody and 45-46m2 
antibody, according to embodiments of the present inven 
tion. 
FIGS. 20A-20I are graphs showing the percent (%) neu 
tralization of 10 viral clones from patient VC10042 using 
NIH45-46'' antibody and 45-46 m2 antibody, in which 
FIGS. 20A, 20B, and 20O are from the indicated clones 
isolated 19 years post-infection, and FIGS. 20D, 20E, 20F, 
20G, 20H, 20I are from the indicated clones isolated 22 
years post-infection, according to embodiments of the pres 
ent invention. 
DETAILED DESCRIPTION 
Aspects of the present invention are directed to anti-CD4 
binding site (CD4bs) antibodies. Embodiments of the pres 
ent invention include anti-CD4bs antibodies which are 
potent VRCO1-like (PVL) antibodies as defined herein. In 
some embodiments of the present invention, an anti-CD4bs 
PVL antibody having a substitution at the amino acid 
position that is equivalent to phenylalanine at position 43 
(Phe43) of the host CD4 receptor protein (CD4), in which 
the Substitution is a hydrophobic amino acid, histidine, 
glycine, arginine, glutamine, asparagine, lysine, glutamic 
acid, and aspartic acid. 
In some embodiments of the present invention, a method 
for increasing the potency and breadth of a PVL antibody 
includes identifying a target amino acid at the position on the 
heavy chain of the PVL antibody that is equivalent to Phe-A3 
on CD4, and Substituting the target amino acid with a 
hydrophobic amino acid, histidine, glycine, arginine, gluta 
mine, asparagine, lysine, glutamic acid; and aspartic acid. 
For example, in the PVL antibody, NIH45-46; glycine at 
position 54 (Gly54) is in the Phe-A3-equivalent position, and 
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Substitution of Gly54 in NIH45-46 (Gly54s) with a 
hydrophobic amino acid such as tryptophan, results in which 
has increased potency and breadth compared to NIH45-46. 
Also, in the PVL antibody, 3BNC60; threonine at position 
54 (Thr54) is in the Phe-A3-equivalent position, and substi 
tution of Thr54 in 3BNC60 with, for example, glycine, 
histidine; or alanine, results in 3BNC60s, 3BCN60s, 
and 3BNC60s, respectively, each of which has increased 
potency and breadth compared to 3BNC60. 
In some embodiments, the NIH45-46G54W is further 
substituted in the light chain at the serine at position 28. The 
substitution of the serine at position 28 can be tryosine (Y), 
and the substitution is referred to herein, as S28Y or S28Y 
LC. The resulting double substituted (i.e., double mutant) 
antibody can be referred to as NIH45-46'''''') or 
as 45-46 m2. 
Abbreviations for amino acids are used throughout this 
disclosure and follow the standard nomenclature known in 
the art. For example, as would be understood by those of 
ordinary skill in the art, Alanine is Ala or A: Arginine is Arg 
or R: Asparagine is ASn or N. Aspartic Acid is Asp or D; 
Cysteine is Cys or C. Glutamic acid is Glu or F: Glutamine 
is Glin or Q: Glycine is Gly or G; Histidine is His or H: 
Isoleucine is Ile or I; Leucine is Leu or L. Lysine is Lys or 
K; Methionine is Met or M. Phenylalanine is Phe or F: 
Proline is Pro or P; Serine is Ser or S: Threonine is Thr or 
T; Tryptophan is Trp or W: Tyrosine is Tyr or Y; and Valine 
is Val or V. 
Hydrophobic amino acids are well known in the art. 
Hydrophobic amino acids include alanine, isoleucine, leu 
cine, methionine, phenylalanine, tryptophan, tyrosine, and 
valine. In some embodiments of the present invention, an 
anti-CD4bs PVL antibody has a hydrophobic amino acid 
substituted at a position equivalent to Phe-A3 of the CD4 
receptor protein, wherein the hydrophobic amino acid is 
alanine, isoleucine, leucine, methionine, phenylalanine, 
tryptophan, tyrosine, or valine. In other embodiments, an 
anti-CD4bs PVL antibody has a hydrophobic amino acid 
substituted at the position equivalent to Phe-A3 of CD4 
receptor protein, wherein the hydrophobic amino acid is 
tryptophan, phenylalanine, or tyrosine. 
In addition to the hydrophobic acids, other amino acids 
that may be substituted at the Phe-A3-equivalent position of 
CD4 in the heavy chain of a PVL antibody, include glycine, 
histidine, arginine, glutamine, asparagine, glutamic acid, 
aspartic acid, lysine, and serine. 
Throughout this disclosure and in embodiments of the 
present invention, the term “antibody’ (Ab) as used herein 
includes monoclonal antibodies, polyclonal antibodies, mul 
tispecific antibodies (for example, bispecific antibodies and 
polyreactive antibodies), and antibody fragments. Thus, the 
term “antibody' and "isolated antibody' are used inter 
changeably herein to refer to an isolated antibody according 
to embodiments of the present invention. An antibody in any 
context within this specification is meant to include, but is 
not be limited to, any specific binding member, immuno 
globulin class and/or isotype (e.g., IgG1, IgG2, IgG3, IgG4. 
IgM, IgA, Ig|D, IgE and IgM); and biologically relevant 
fragment or specific binding member thereof, including but 
not limited to Fab, F(ab')2, Fv, and schv (single chain or 
related entity). It is understood in the art that an antibody is 
a glycoprotein comprising at least two heavy (H) chains and 
two light (L) chains inter-connected by disulfide bonds, or 
an antigen binding portion thereof. A heavy chain is com 
prised of a heavy chain variable region (VH) and a heavy 
chain constant region (CH1, CH2 and CH3). A light chain is 
comprised of a light chain variable region (VL) and a tight 
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chain constant region (CL). The variable regions of both the 
heavy and light chains comprise framework regions (FWR) 
and complementarity determining regions (CDR). The four 
FWR regions are relatively conserved while CDR regions 
(CDR1, CDR2 and CDR3) represent hypervariable regions 
and are arranged from the NH2 terminus to the COOH 
terminus as follows: FWR1, CDR1, FWR2, CDR2, FWR3, 
CDR3, FWR4. The variable regions of the heavy and light 
chains contain a binding domain that interacts with an 
antigen while, depending on the isotype, the constant 
region(s) may mediate the binding of the immunoglobulin to 
host tissues or factors. CDR1, CDR2, and CDR3 of the light 
chain are referred to as CDRL1, CDRL2 and CDRL3, 
respectively. CDR1, CDR2, CDR3 of the heavy chain are 
referred to as CDRH1, CDRH2, and CDRH3, respectively. 
Also included in the definition of “antibody' as used 
herein are chimeric antibodies, humanized antibodies, and 
recombinant antibodies, human antibodies generated from a 
transgenic non-human animal, as well as antibodies selected 
from libraries using enrichment technologies available to the 
artisan. The term “variable' refers to the fact that certain 
segments of the variable (V) domains differ extensively in 
sequence among antibodies. The V domain mediates antigen 
binding and defines specificity of a particular antibody for its 
particular antigen. However, the variability is not evenly 
distributed across the 110-amino acid span of the variable 
regions. Instead, the V regions consist of relatively invariant 
stretches called framework regions (FRs) of 15-30 amino 
acids separated by shorter regions of extreme variability 
called “hypervariable regions' that are each 9-12 amino 
acids long. The variable regions of native heavy and light 
chains each comprise four FRs, largely adopting a beta sheet 
configuration, connected by three hyperVariable regions, 
which form loops connecting, and in some cases forming 
part of the beta sheet structure. The hypervariable regions in 
each chain are held together in close proximity by the FRS 
and, with the hypervariable regions from the other chain, 
contribute to the formation of the antigen-binding site of 
antibodies. The term “hypervariable region' as used herein 
refers to the amino acid residues of an antibody that are 
responsible for antigen binding. The hyperVariable region 
generally comprises amino acid residues from a "comple 
mentarity determining region” (“CDR). 
An antibody of the present invention may be a “human 
ized antibody’. A humanized antibody is considered to be a 
human antibody that has one or more amino acid residues 
introduced into it from a source that is non-human. These 
non-human amino acid residues often are referred to as 
“import residues, which typically are taken from an 
“import' variable region. Humanization may be performed 
following known methods by Substituting import hyperVari 
able region sequences for the corresponding sequences of a 
human antibody. (See, for example, Jones et al., Nature, 
321:522-525 20 (1986); Reichmann et al., Nature, 332:323 
327 (1988); Verhoeyen et al., Science, 239:1534-1536 
(1988)) the entire contents of each are incorporate herein by 
reference). Accordingly, Such "humanized antibodies are 
chimeric antibodies in which Substantially less than an intact 
human variable region has been substituted by the corre 
sponding sequence from a non-human species. 
An antibody of the present invention includes an “anti 
body fragment' which includes a portion of an intact anti 
body, Such as the antigen binding or variable region of the 
intact antibody. Examples of antibody fragments include, 
but are not limited to, Fab, Fab'. F(ab')2, and Fv fragments: 
diabodies; linear antibodies; single-chain antibody mol 
ecules; and multispecific antibodies formed from antibody 
US 9,493,549 B2 
fragments. (See, for example, U.S. Pat. No. 5,641,870, the 
entire content of which is incorporated herein by reference). 
Throughout this disclosure and in embodiments of the 
present invention, a “potent VRC01-like” (“PVL) antibody 
of the present invention is an anti-CD4 binding site antibody 
that has the following conserved heavy chain (HC) and light 
chain (LC) residues: Arg71, Trp50, ASn58, 
Trp 100B, Glu96, Trp67./Phe67, as well as exactly 
5 amino acids in CDRL3 domain (using Kabat numbering). 
(The Kabat numbering system is described in Abhinandan, 
K. R. and Martin, A. C. R. (2008), “Analysis and improve 
ments to Kabat and structurally correct numbering of anti 
body variable domains. Molecular Immunology, 45: 3832 
3839, the entire contents of which are herein incorporated by 
reference). A PVL antibody of the present invention is any 
antibody as defined herein, that has the listed FAT features 
irrespective of the synthesis or derivation of the antibody, 
irrespective of the other unrestricted domains of the anti 
body, and irrespective of whether or not other domains of the 
antibody are present, so long as the antibody has the 
signature residues and features. 
Throughout the disclosure and in embodiments of the 
present invention, the terms “Phe43-equivalent position 
and “Phe43.sub.CD4 equivalent position' are used inter 
changeably and refer to an amino acid position within the 
heavy chain of a PVL antibody that replicates or mimics the 
binding pocket and interface contributed by Phe-A3 of the 
host CD4 receptor when the CD4 receptor protein is com 
plexed with the HIV viral spike protein gp120. As known in 
the art, assigned amino acid positions of an antibody do not 
necessarily correspond to the amino acid residue as num 
bered from the amino-terminus. Following the Kabat anti 
body residue/position numbering system, the amino acid 
residue number may be the same as the amino acid position, 
but is not necessarily so. (See, Abhinandan, K. R. and 
Martin, A. C. R. (2008) Molecular immunology, 45: 3832 
3839). The structure of the antibody peptide determines the 
position number. The information for determining position 
number using the Kabat system for each amino acid in a 
given sequence can be determined using the information 
found in Abhinandan and Martin, 2008. Using this position 
numbering system, the Phe-A3-equivalent position in a PVL 
antibody heavy chain sequence can be determined, and 
substituted with a hydrophobic amino acid to create a similar 
binding pocket as conferred by Phe-A3 in CD4. Methods for 
this mutagenesis are well known in the art (e.g. Example 2). 
Subsequent heavy chain sequences can be analyzed using 
the Kabat numbering system to determine the equivalent 
position to this position 54. Alternatively, the Phe-A3 
equivalent position can also be determined by structural 
analysis such as X-ray crystallography. Any means of deter 
mining the Phe-A3-equivalent position may be used so 
long as the Kabat system is followed as applicable. 
For example, the Phe-A3-equivalent position in NIH45-46 
is position 54 as determined by X-ray crystallography and 
shown herein. The native NIH45-46 heavy chain sequence 
(SEQ NO: 6) contains a glycine at position 54 (Gly54). The 
native 3BNC60 heavy chain sequence (SEQ ID NO: 8) 
contains a threonine at position 54 (Thr54). As such, these 
PVL antibodies substituted with a hydrophobic amino acid, 
glycine, histidine, arginine, glutamine, or asparagine at these 
Phe-43 equivalent positions mimic the desired contact inter 
face between the CD4 receptor protein and the CD4 binding 
site of gp120 (see, e.g., Example 2). 
In some embodiments of the present invention, position 
54 (Kabat numbering) of the heavy chain of a PVL antibody 
has a substituted hydrophobic amino acid. Position 54 is 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
10 
determined by analyzing a heavy chain amino acid sequence 
of a PVIL antibody using the Kabat numbering system. 
In some embodiments of the present invention, a hydro 
phobic amino acid is substituted for the “native' amino acid 
present at the Phe-A3,-equivalent position on the heavy 
chain of a PVL antibody, where a PVL antibody is an 
antibody as defined herein having the PVL signature features 
as described herein, and “native' refers to the amino acid 
that is present in the PVL antibody prior to substitution. The 
native amino acid in the heavy chain may also be hydro 
phobic, and may be substituted with another hydrophobic 
amino acid, or with glycine, histidine, arginine, glutamine, 
asparagine, lysine, glutamic acid, and aspartic acid. 
In some embodiments of the present invention, non 
limiting examples of PVL antibodies include VRCO1, 
VRCO2, NIH45-46, 3BNC60, 3BNC117, 3BNC62, 
3BNC95, 3BNC176, 12A21, VRC-PG04, VRC-CH30, 
VRC-CH31, VRC-CH32, VRC-CH33, VRC-CH34, VRC03 
heavy chain (HC) with VRC01 light chain (LC), gVRC-H5 
(d74)/VRC-PG04LC, and gVRC-H12(d74)/VRC-PG04LC, 
VRC03, VRC01 heavy chain (HC) with VRC03 light chain 
(LC), 3BNC55, 3BNC91, 3BNC104, 3BNC89, 12A21, and 
VRC-PG04b as listed below in Table 1. 
TABLE 1. 
Examples of PVL Antibodies 
Light Chain Heavy Chain 
Antibody Name SEQ ID NO: SEQ ID NO: 
WRCO1 1 2 
WRCO2 3 4 
NIH-45-46 5 6 
3BNC60 7 8 
3BNC117 9 10 
3BNC62 11 12 
3BNC95 13 14 
3BNC176 15 16 
12A12 17 18 
WRC-PG04 19 2O 
WRC-CH3O 21 22 
WRC-CH31 23 24 
WRC-CH32 25 26 
WRC-CH33 27 28 
WRC-CH34 29 30 
WRCO3 31 32 
3BNC55 33 34 
3BNC91 35 36 
3BNC104 37 38 
3BNC89 39 40 
12A21 41 42 
WRC-PG04b. 43 44 
WRCO3HC-VRCO1LC 1 32 
WRCO1HCVRCO3LC 31 2 
gVRC-H5(d74), 19 45 
WRC-PGO4LC 
In some embodiments of the present invention, a PVL 
antibody has a heavy chain selected from one of the heavy 
chains listed above in Table 1 (SEQ ID NOs 2, 4, 6, 8, 10, 
12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 
44, 45, and 46). Any PVL heavy chain may be matched with 
a PVL light chain so long as the signature PVL residue 
features are maintained. In some embodiments, any one of 
the PVL heavy chains of Table 1 is expressed with any one 
of the PVL light chains of SEQID NOs 1, 3, 5, 7, 9, 11, 13, 
15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43. 
In other embodiments, any PVL antibody heavy chain can be 
combined with any PVL antibody light chain. 
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In embodiments of the present invention, the terms 
“nucleic acid and “polynucleotide' are used interchange 
ably herein to refer to single-stranded or double-stranded 
RNA, DNA, or mixed polymers. Polynucleotides can 
include genomic sequences, extra-genomic and plasmid 
sequences, and Smaller engineered gene segments that 
express, or can be adapted to express polypeptides. 
An "isolated nucleic acid' is a nucleic acid that is sub 
stantially separated from other genome DNA sequences as 
well as proteins or complexes such as ribosomes and poly 
merases, which naturally accompany a native sequence. 
In some embodiments of the present invention, nucleic 
acid molecules encode part or all of the light and heavy 
chains of the described inventive antibodies, and fragments 
thereof. Due to redundancy of the genetic code, variants of 
these sequences will exist that encode the same amino acid 
Sequences. 
The present invention also includes isolated nucleic acid 
molecules encoding the polypeptides of the heavy and the 
light chain of the PVL antibodies listed in Table 1. In some 
embodiments, an isolated nucleic acid molecule encodes for 
any of the PVL heavy chain and light chain polypeptides 
including those of SEQID NOS 2, 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 45, and 46, 
and SEQ NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 
29, 31, 33,35, 37, 39, 41, and 43, respectively, in which the 
Phe-A3,-equivalent amino acid (i.e., the target amino acid) 
of the heavy chain is substituted with a hydrophobic amino 
acid. 
Embodiments of the present invention also include vec 
tors and host cells including a nucleic acid encoding a PVL 
antibody of the present invention, as well as recombinant 
techniques for the production of polypeptide of the inven 
tion. Vectors of the invention include those capable of 
replication in any type of cell or organism, including, for 
example, plasmids, phage, cosmids, and mini chromosomes. 
In some embodiments, vectors comprising a polynucleotide 
5 of the described invention are vectors suitable for propa 
gation or replication of the polynucleotide, or vectors Suit 
able for expressing a polypeptide of the described invention. 
Such vectors are known in the art and commercially avail 
able. 
In embodiments of the present invention, “vector” 
includes shuttle and expression vectors. Typically, the plas 
mid construct will include an origin of replication (for 
example, the ColE1 origin of replication) and a selectable 
marker (for example, amplicillin or tetracycline resistance), 
for replication and selection, respectively, of the plasmids in 
bacteria. An "expression vector” refers to a vector that 
contains the necessary control sequences or regulatory ele 
ments for expression of the antibodies including antibody 
fragment of the invention, in bacterial or eukaryotic cells. 
In some embodiments of the present invention, in order to 
express a polypeptide of the invention, the nucleotide 
sequences encoding the polypeptide, or functional equiva 
lents, may be inserted into an appropriate expression vector, 
i.e., a vector that contains the necessary elements for the 
transcription and translation of the inserted coding sequence. 
Methods well known to those skilled in the art may be used 
to construct expression vectors containing sequences encod 
ing a polypeptide of interest and appropriate transcriptional 
and translational control elements. These methods include in 
vitro recombinant DNA techniques, synthetic techniques, 
and in vivo genetic recombination. Such techniques are 
described, for example, in Sambrook, J., et al. (2001) 
Molecular Cloning, A Laboratory Manual, Cold Spring 
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Harbor Press, Plainview, N.Y., the entire contents of which 
are incorporated herein by reference. 
As used herein, the term “cell can be any cell, including, 
but not limited to, eukaryotic cells, such as, but not limited 
to, mammalian cells or human cells. 
In some embodiments of the present invention, the anti 
bodies disclosed herein are produced recombinantly using 
vectors and methods available in the art. (see, e.g. Sambrook 
et al., 2001, Supra). Human antibodies also can be generated 
by in vitro activated B cells (see, for example, U.S. Pat. Nos. 
5,567,610 and 5,229.275). Reagents, cloning vectors, and 
kits for genetic manipulation are available from commercial 
vendors such as BioRad, Stratagene, Invitrogen, ClonTech 
and Sigma-Aldrich Co. 
In some embodiments of the present invention, human 
antibodies are produced in transgenic animals (for example, 
mice) that are capable of producing a full repertoire of 
human antibodies in the absence of endogenous immuno 
globulin production. For example, it has been described that 
the homozygous deletion of the antibody heavy-chain join 
ing region (JH) gene in chimeric and germ-line mutant mice 
results in complete inhibition of endogenous antibody pro 
duction. Transfer of the human germ-line immunoglobulin 
gene array into Such germline mutant mice results in the 
production of human antibodies upon antigen challenge. 
See, for example, Jakobovits et al., Proc. Natl. Acad. Sci. 
USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255 
258 (1993); Bruggemann et al., Year in Immuno. 7:33 
(1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669; 
U.S. Pat. No. 5,545,807; and WO 97/17852, the entire 
contents of all of which are incorporated herein by reference. 
Such animals can be genetically engineered to produce 
human antibodies comprising a polypeptide of a PVIL anti 
body of the present invention. 
In some embodiments of the present invention, a method 
includes the preparation and administration of an HIV 
antibody composition (e.g., a PVIL antibody having a hydro 
phobic amino acid Substituted at the Phe-A3-equivalent 
position of the PVL heavy chain) that is suitable for admin 
istration to a human or non-human primate patient having an 
HIV infection, or at risk of infection, in an amount and 
according to a schedule Sufficient to induce a protective 
immune response against HIV, or reduction of the HIV virus, 
in a human. 
In some embodiments of the present invention, a vaccine 
includes at least one antibody as disclosed herein and a 
pharmaceutically acceptable carrier. In some embodiments 
of the present invention, the vaccine is a vaccine including 
at least one PVL antibody as described herein and a phar 
maceutically acceptable carrier. The vaccine can include a 
plurality of the antibodies having the characteristics 
described herein in any combination and can further include 
HIV neutralizing antibodies such as a PVL antibody having 
the Phe-A3,-equivalent residue on the heavy chain substi 
tuted with a hydrophobic amino acid. 
In some embodiments of the present invention, carriers as 
used herein include pharmaceutically acceptable carriers, 
excipients or stabilizers that are nontoxic to the cell or 
mammal being exposed thereto at the dosages and concen 
trations employed. Often the physiologically acceptable 
carrier is an aqueous pH buffered solution. Examples of 
physiologically acceptable carriers include, but are not lim 
ited to, buffers such as phosphate, citrate, and other organic 
acids; antioxidants including, but not limited to, ascorbic 
acid; low molecular weight (less than about 10 residues) 
polypeptide; proteins, such as, but not limited to, serum 
albumin, gelatin, or immunoglobulins; hydrophilic polymers 
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Such as, but not limited to: polyvinylpyrrolidone; amino 
acids such as, but not limited to: glycine, glutamine, aspara 
gine, arginine or lysine; monosaccharides, disaccharides, 
and other carbohydrates including, but not limited to: glu 
cose, mannose, or dextrins; chelating agents such as, but not 
limited to: EDTA (ethylenediamineteteraacetic acid); sugar 
alcohols such as, but not limited to: mannitol or sorbitol; 
salt-forming counterions such as, but not limited to: Sodium; 
and/or nonionic Surfactants such as, but not limited to 
TWEENR) (polysorbate); polyethylene glycol (PEG), and 
PLURONICS(R) (poloxamers). 
In some embodiments of the present invention, the com 
positions may include a single antibody or a combination of 
antibodies, which can be the same or different, in order to 
prophylactically or therapeutically treat the progression of 
various subtypes of HIV infection after vaccination. Such 
combinations can be selected according to the desired 
immunity. When an antibody is administered to an animal or 
a human, it can be combined with one or more pharmaceu 
tically acceptable carriers, excipients or adjuvants as are 
known to one of ordinary skilled in the art. The composition 
can further include broadly neutralizing antibodies known in 
the art, including, for example, a PVIL antibody having the 
Phe-A3-equivalent residue Substituted with a hydrophobic 
amino acid or glycine, histidine, arginine, glutamine, aspara 
gine, glutamic acid, and aspartic acid, and the serine at 
position 28 of the light chain substituted with tyrosine 
(S28Y LC). 
In some embodiments of the present invention, an anti 
body-based pharmaceutical composition includes a thera 
peutically effective amount of an isolated HIV antibody 
which provides a prophylactic or therapeutic treatment 
choice to reduce infection of the HIV virus. The antibody 
based pharmaceutical composition of the present invention 
may be formulated by any number of strategies known in the 
art (e.g., see McGoff and Scher, 2000, Solution Formulation 
of Proteins/Peptides: In McNally, E. J., ed. Protein Formu 
lation and Delivery. New York, N.Y.: Marcel Dekker; pp. 
139-158: Akers and Defilippis, 2000, Peptides and Proteins 
as Parenteral Solutions. In: Pharmaceutical Formulation 
Development of Peptides and Proteins. Philadelphia, Pa...: 
Taylor and Francis; pp. 145-177; Akers, et al., 2002, Pharm. 
Biotechnol. 14:47-127, the entire contents of all of which are 
incorporated herein by reference). 
In some embodiments of the present invention, a method 
for treating a mammal infected with a virus infection, Such 
as, for example, HIV, comprising administering to said 
mammal a pharmaceutical composition comprising an anti 
body composition as disclosed herein. According to some 
embodiments, the method for treating a mammal infected 
with HIV includes administering to said mammal a phar 
maceutical composition that includes an antibody as dis 
closed herein, or a fragment thereof. The compositions of 
embodiments of the present invention may include more 
than one antibody having the characteristics disclosed 
herein. For example, a plurality or pool of PVL antibodies, 
each antibody having the Phe-A3-equivalent residue Sub 
stituted with a hydrophobic amino acid. 
In some embodiments of the present invention, in vivo 
treatment of human and non-human patients includes admin 
istering or providing a pharmaceutical formulation including 
an antibody according to embodiments of the present inven 
tion. When used for in vivo therapy, the antibodies of the 
invention are administered to the patient in therapeutically 
effective amounts (i.e., amounts that eliminate or reduce the 
patient’s viral burden). The antibodies are administered to a 
human patient, in accord with known methods, such as 
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intravenous administration, for example, as a bolus or by 
continuous infusion over a period of time, by intramuscular, 
intraperitoneal, intracerobrospinal, Subcutaneous, intra-ar 
ticular, intrasynovial, intrathecal, oral topical, or inhalation 
routes. The antibodies can be administered parenterally, 
when possible, at the target cell site, or intravenously. In 
Some embodiments, a PVIL antibody composition as 
described herein is administered by intravenous or subcu 
taneous administration. 
In some embodiments of the present invention, a thera 
peutically effective amount of an antibody is administered to 
a patient. In some embodiments, the amount of antibody 
administered is in the range of about 0.1 mg/kg to about 50 
mg/kg of patient body weight. Depending on the type and 
severity of the infection, about 0.1 mg/kg to about 50 mg/kg 
body weight (for example, about 0.1-15 mg/kg/dose) of 
antibody is an 5 initial candidate dosage for administration 
to the patient, whether, for example, by one or more separate 
administrations, or by continuous infusion. The progress of 
this therapy is readily monitored by conventional methods 
and assays and based on criteria known to the physician or 
other persons of skill in the art. The above parameters for 
assessing Successful treatment and improvement in the dis 
ease are readily measurable by routine procedures familiar 
to a physician. 
In some embodiments of the present invention, passive 
immunization using a PVIL antibody as disclosed herein, is 
used as an effective and safe strategy for the prevention and 
treatment of HIV disease. (See, for example, Keller et al., 
Clin. Microbiol. Rev. 13:602-14 (2000); Casadevall, Nat. 
Biotechnol. 20:114 (2002); Shibata et al., Nat. Med. 5:204 
10 (1999); and Igarashi et al., Nat. Med. 5:211-16 (1999), 
each of which are incorporated herein by reference). 
The following Examples are presented for illustrative 
purposes only, and do not limit the scope or content of the 
present application. 
EXAMPLES 
Reference is made to Riskin et al., 2011, Science. 334: 
12989-1293; and West et al., 2012, PNAS, (doi:10.1073/ 
pnas. 120898.4109), the entire contents of both of which are 
incorporated herein by reference. 
Example 1 
Structural Comparisons of NIH45-46 and VRC01 
To determine structural correlates of high potency and 
breadth in HAADs, structures of NIH45-46 alone and bound 
to the Glade A/E 93TH057 gp120 core were solved (FIGS. 
1A, 1B and 2). NIH45-46 is a more potent clonal variant of 
VRC01 that was isolated from the same donor using a YU2 
trimer (Sheid et al., 2011, supra), instead of a resurfaced 
gp120 core (RSC3) as a bait. Comparisons of NIH45-46 Fab 
in its free versus gp120-bound states demonstrate that gp120 
binding does not require major conformational changes 
(FIG. 1A). However, gp120 binding induced minor confor 
mational in CDRL1, CDRH3, and in heavy chain framework 
region 3 (FWR3). As predicted by high sequence identity 
(85% in V: 96% in V,) (FIGS. 3A and 3B), NIH45-46 
resembles VRC01 (FIGS. 4A and 4B). However, relative to 
VRC01, NIH45-46 includes a four-residue insertion within 
CDRH3 (FIG. 5) that was acquired by somatic hypermuta 
tion. (See, Sheid et al., 2011, Science, 333:1633-1637, the 
entire contents of which are incorporated herein by refer 
ence). 
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The crystal structure of the NIH45-46-93THO57 gp120 
complex verified that NIH45-46 targets the CD4bs on gp120 
(FIGS. 1B and 5). The primary binding surface is the outer 
domain, including the CD4 binding loop (FIG. 6A), loop D 
and loop V5, but CDRH3xas a reaches toward the gp120 
inner domain (FIG. 1B, 6A-6C). Important interactions in 
the VRCO1-93THO57 structure are conserved in NIH45-46 
(FIG. 4B); e.g., residues C-terminal to CDRH12 of VRC01 
and NIH45-46 mimic the interaction of main-chain atoms in 
the C" B-strand of CD4 domain, which hydrogen bond with 
the CD4-binding loop of gp120 (FIGS. 6A, 6B and 6C). In 
both NIH45-46 and VRC01, hydrogen bonds between 
CDRH2 and gp120 are water-mediated (except for the 
Gly54v4s-46/Gly54 veco carbonyl oxygen-Asp368 120 
backbone nitrogen H-bond (FIGS. 6A, 6B and 6C)), and 
Arg71-roo/Arg71v4s-46 preserves the Arg594 interac 
tion with Asp36820. However, the Phe43, interaction 
16 
TABLE 3 
CDRH3 sequence 
5 NIH45-46 WT FCTRGKYCTARDYYNWDFEHWGRGAP 
NIH45-46 Y99cA. FCTRGKYCTARDAYNWDFEHWGRGAP 
NIH45-46 A99a 
99c. 
FCTRGKYCT- - - -YNWDFEHWGRGAP 
10 
First, the Tyr99das a sidechain hydrogen bonds with 
the loop D Ala2812o carbonyl oxygen 7), a main-chain 
is atom, thus preventing escape through mutation. Indeed, 
NIH45-46-sensitive strains accommodate different 
sidechains at position 281.20 (Table 4, below). 
TABL E 4. 
Comparison of in vitro neutralization for viral strains with differences at 28 lap 20 
Residue ICso 
Strain gp120 sequence surrounding residue 281 281ge 120 lug/mL, 
Du156. 12 OLLLNGSLAEEEIIIKSENLTDNIKTIIVOLNOSIGINCTRPNNNTRKSV I O. O1 
ZM197M.Pf OLLLNGSLAEEEIIIRSENLTDNTKTIIVHLNESVEIECVRPNNNTRKSV T O. 14 
ZM214 M.PL15 OLLLNGSLAEKEIMIRSENLTNNAKTIIVOLTEAVNITCMRPGNNTRRSV A. O. OS 
ZM249MPL1 OLLLNGSLAEKEIIIRSENITDNWKIIIVHLNESVEINCTRPNNNTRKSI W O. O2 
ZM53M PB12 OLLLNGSTAEEDIIIRSENLTNNAKTIIVHLNESIEIECTRPGNNTRKSI A. O. 65 
ZM109F. PB4 OLLLNGSLAEEEIVIRSENLTDNAKTIIVHLNKSVEIECIRPGNNTRKSI A. O. 22 
ZM135M.PL1Oa OLLLNGSLSEEGIIIRSKNLTDNTKTIIVHLNESVAIVCTRPNNNTRKSI T O. 36 
with a hydrophobic pocket between C-helix 32 (CD4 
binding loop) and f-strand 21.20 (bridging sheet) (FIGS. 
9A and 9B) is not mimicked by either antibody. Differences 
between VRCO1 and NIH45-46 include the conformation of 40 
heavy chain residue Tyr74, a FWR3 residue that was sub 
stituted during somatic hypermutation (Sheid et al., 2011, 
supra), and a tyrosine to serine substitution in CDRL1 
(FIGS. 10A, 10B, 11A, and 11B). 
Anotable difference between VPCO1 and NIH45-46 is the 
four-residue insertion (residues 99a-99d) in CDRH3. Three 
inserted residues contribute to binding to gp120-inset), 
consistent with deletion of the insertion resulting in about 
10-fold reduced neutralization potencies (Tables 2 and 3, so 
below). 
45 
TABLE 2 
In vitro neutralization ICs values mL 55 
NIH45-46 NIH45-46 NIH45-46 
Virus Clade WT Y99A A99a-99d 
AC1O.O.29 B O.9 4.4 13 
TRO.11 B 1.9 >50 >50 60 
SC422661.8 B O.OS O.08 1.4 
QHO692.42 B 0.7 2.1 3.7 
ZM214.M.PL15.11 C O.3 1.1 2.2 
CAP4S.2.OO.G3 C >50 >50 >50 
T257-31 CRF02 O.S 2.4 7.0 
(A/G) 65 
The importance of Tyr99ds for potency is demon 
strated by alanine substitution (NIH45-46 Y99dA), which 
reduces the neutralization potency of NIH45-46 to values 
intermediate between wild-type NIH45-46 and the deletion 
mutant (Table 2), Second, Asp99case interacts electro 
statically with Lys972 at the base of C-helix 120, and 
third, Arg99bwn as as hydrogen bonds with ASn99,20 
(FIG. 8). The conformation of the insertion is stabilized by 
two intramolecular hydrogen bonds. In one, the 
Tyr99das a sidechain hydrogen bonds with the amino 
group of Lys52s. within CDRH2 (FIG. 7), also seen in 
the unbound structure of NIH45-46 (FIG. 7-inset), thus the 
Tyr99das a hydroxyl is poised for interacting with 
Ala281.20. A second hydrogen bond between 
Tyr)74s-46 and Asp99cvttas 46 in the gp120-bound Fab 
positions the negatively-charged aspartic acid for interaction 
with Lys972 (FIG. 8). The region of gp120 with which 
CDRH3s interacts was not included in the previously 
defined Vulnerable site of initial CD4 attachment on the 
gp120 outer domain (FIG. 9C). Thus, gp120 residues that 
contact CDRH3 as a residues required for potent neutral 
ization (Table 2), e.g., Lys972, were mutated in RSC3 (FIG. 12), the resurfaced gp120 used for isolating bNAbs 
and as a candidate HIV immunogen. 
The insertion in CDRH3 contributes to a higher total 
buried surface area between the NIH45-46 heavy chain and 
gp120 compared with VRC01. (Table 5, below). The extra 
contacts with gp120 created by the CDRH3 insertion allow 
the NIH45-46 footprint on gp120 to more closely resemble 
the CD4 footprint on gp120 than does the VRC01 footprint 
(FIGS. 9C, 9D, and 9E, and Tables 5A and 5B, below). 
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TABLE 5A 
18 
Buried Surface Area (A 
Interface CDR2 -- 
FWR1 CDR1 FWR2 CDR2 FWR3 CDR3 Total Fab on gp120 FWR3s, 
NIH45-46 HC O 35 51 181 551 326 1144 1097 576 
WRCO1 HC O 2O 98 136 521 117 892 882 545 
NIH45-46 LC 35 8 O O O 159 2O3 192 O 
WRCO1 LC 36 114 O O O 16S 314 367 O 
*Residues that correspond to the CDR2 region as defined in Zhou et al., Science, 2010, 329: 811 
817. 
TABLE 5B 
Inner 
domain & Loop Outer domain Interface 
bridging D + B-15/C-3 + exit Total on Fab 
sheet NAG NAG V5 B-24 loop gp120 or CD45 
NIH45-46 328 335 222 292 81 35 1290 1346 
WRCO1 157 433 208 328 43 57 1225 12O6 
CD4 400 136 263 155 14 97 973 1059 
The observation that NIH45-46 shows more extensive 
contacts relative to VRC01 with the inner domain and 
bridging sheet of gp120 (FIGS. 9D and 9E), yet exhibits 
higher potency and breadth (Sheid et al., 2001, supra), is 
inconsistent with the Suggestion that increased contact area 
with regions outside of the outer domain of gp120 correlate 
with decreased neutralization potency and/or breadth (Zhou 
et al., 2010 supra; and Wu et al., 2011, Science, 333:1593 
1602). Indeed, the Observed CDRH3 contacts with the inner 
domain imply that the crystallographically-observed confor 
mation of this region, whether pre-existing or induced, 
actively played a role in the affinity maturation events that 
resulted in the four-residue insertion with CDRH3. 
Example 2 
Hydrophobic Amino Acid Substitution at Position 
54 of NIH45-46 
Although NIH45-46 increases its contacts with the inner 
domain/bridging sheet area of gp120, like VRCO1, it lacks 
a critical CD4 contact to a hydrophobic pocket at the 
boundary between the gp120 bridging sheet and outer 
domain made by burying Phe-A3. This residue alone 
accounts for 23% of the interatomic contacts between CIA 
and gp120, serving as a “linchpin” that welds CD4 to gp120 
(Kwong et al., 1998, Nature, 393:648-659). On gp120, the 
Phe-A3 binding cavity is a binding site of small-molecule 
CD4 mimics (Madani et al., 2008, Structure, 16:1689-1701), 
and a desirable target for compounds to disrupt CD4-gp120 
Virus 
SC422661.8 
AC1O.O.29 
TRO.11 
D172.17 
CAP210.2.OO.E8 
CAP45.2.OO.G3 
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interactions (Kwong et al., 1998, Supra), yet it remains 
unfilled in the 93THO57 complexes with VRC01 (Zhou et 
al., 2010, supra) and NIH45-46. In a superimposition of a 
CD4-gp120 structure and NIH45-46-gp120 (FIG. 9B), the 
CC atom of heavy chain residue Gly54s is only about 
1.4. A from the Phe43, Co., suggesting that this important 
interaction might be mimicked by Substituting 
Gly54Ms. With a large hydrophobic residue. Indeed, 
residue 54 of VRC03 is a tryptophan, and Trp54 to is 
accommodated within gp120’s Phe-A3 binding cavity to 
mimic Phe-A3, while still maintaining its main-chain 
hydrogen bond with Asp368 (PDB 3SE8) (FIGS. 
6A-6C). If increasing contacts with the inner domain/bridg 
ing sheet enhances antibody activity, as Suggested by analy 
sis of the NIH45-46-gp120 structure, then substituting 
Gly54s with a large hydrophobic residue should 
increase the potency and breadth of NIH45-46. 
A series of NIH45-46 mutants were constructed to test the 
possibility that a hydrophobic sidechain at position 54 in 
NIH45-46 would improve activity. First it was verified that 
substitutions at residue 54 did not interfere with antigen 
binding by assessing the ability of one mutant, NIH45 
46", to bind core gp120s. Surface plasmon resonance (SPR) binding analyses demonstrated that NIH45-46'' 
Fab bound core gp120s with slightly higher affinities than 
did NIH45-46 Fab, with differences largely due to slower 
dissociation rates (FIGS. 13A, 13B, and 13C). Next mutant 
IgGs were evaluated in neutralization assays using a panel of 
six viruses chosen to include NIH45-46-sensitive and resis 
tant strains (Table 6, below). 
TABLE 6 
NIH45-46 ICso (Lig/mL) 
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0.36 ug/mL), may similarly relate to the unusual Lys992 
residue replacing the asparagine that favorably interacts with 
Arg99base in the NIH45-46-gp120 crystal structure. 
From the neutralization assays, it is noted that NIH45 
46'' gained de novo neutralization activity against six 
NIH45-46 resistant strains, including the only three that 
were sensitive to VRCO1 but resistant to NIH45-46 in the 
panel tested in Sheid et al., 2011, supra. For some strains that 
NIH45-46 neutralizes poorly, NIH45-46'' was signifi 
cantly more potent (e.g., improvements of >700-fold for 
T255-34 and 2000-fold for 3718.v3.c11). The enhanced 
neutralization activity of NIH45-46'' implies that Trp54 
forms a favorable hydrophobic interaction with Phe-A3 cavity 
of gp120 as seen in VRC03-gp120 (PDB 3SE8). NIH45 
46 showed some increased activity (Tables 6, 7 and 8). 
10 
26 
Substituting Gly54 with tryptophan adds about 140 A of 
buried surface area on V, when complexed with gp120, and 
is consistent with the reduced dissociation rates observed in 
surface plasmon resonance (SPR) experiments (FIGS. 13A, 
13B, and 13C). By providing a tryptophan in the Phe-A3 
cavity of gp120, NIH45-46'' may use higher affinities 
and/or slower dissociation rates to overcome incompatible 
Surface variations that render some viruses less sensitive or 
resistant to its effects. 
Heavy chain residue 54 is not conserved in HAADs; in 
addition to glycine (NIH45-46 and VRC01), residue 54 can 
be threonine (3BNC60, 3BNC117, 3BNC115; VRC-PG04), 
tyrosine (12A12), phenylalanine (12A21), or arginine 
(1B2530 and 1 NC9), as reported in Sheid et al., 2011, supra: 
and Wu et al., 2011, supra. Tryptophan substitution in some 
HAADs was tested and shown in Table 10, below. 
TABLE 10 
In vitro neutralization ICs values (Lig/mL. 
3BNC117 3BNC117 3BNCSS 3BNCSS 12A12 12A12 
T54W WT T54W WT T54W WT Y54W 
O.1 O.O7 O.O7 O.3 O6 O.2 O.2 
3.1 6.5 2.8 >50 >50 O.6 O.S 
O.O6 O.6 O6 7.6 >50 O.3 O.2 
O.04 O.04 O.9 2 >50 O.2 O.1 
S.O 11 2.8 >50 >50 >50 >50 
19 16 23 >50 >50 0.4 O.2 
Virus Clade WT 
SC422661.8 B O.1 
AC1O.O.29 B 13 
TRO.11 B O.O7 
D172.17 C O.OS 
CAP210.2.OO.E.8 C 4.7 
CAP4S.2.OO.G3 C 10 
30 
35 
40 
45 
Passive immunization and/or gene therapy to deliver HIV 
antibodies is increasingly being considered as an option for 
prevention of HIV infection. To reduce the concentrations 
and numbers of antibodies required for protection to realistic 
and affordable levels, highly potent and broadly neutralizing 
antibodies are the reagents of choice for passive delivery. 
Although it is difficult to compare the potencies and breadth 
of antibodies characterized using different virus panels, the 
natural form of NIH45-46 exhibits superior potency to 
VRC01 when compared against a panel of 82 Tier 2 and 3 
viruses representing all known HIV clades (Sheid et al., 
2011, supra). One set of HIV antibodies, the PGT antibodies 
that recognize the gp120 V3 loop and associated carbohy 
drates, exhibited median ICss up to 10-fold lower than 
VRC01 (Walker et at, 2011, Nature, 477:466-471, the entire 
contents of which are incorporated herein by reference), but 
are less potent and broad than NIH45-46'' (FIG. 15B, 
and Table 11, below). 
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Table 11 above shows a comparison of mean and median 
ICs (ug/mL) values for PGT antibodies and VRC01. A 
direct comparison between NIH45-46 and the PGT antibod 
ies is not available. However, VRC01 (which was shown in 
a direct comparison to be less potent than NIH45-46) was 
directly compared to the PGT antibodies using the same 
virus panel. (Sheid et al., 2011, supra.) Mean ICso values 
were calculated using data taken from Sheid et al., 2011, 
Supra. Geometric and arithmetic means were calculated to 
include data for all viral strains (listed as Include >50, in 
which case, values reported as ICs >50 g/mL were entered 
as 50 ug/mL in the calculation) and to exclude viral strains 
in which the ICso was >50 g/mL, (listed as Exclude >50, in 
which case the percent of viral strains with ICS-50 ug/mL 
is also reported). Mean ICsos are compared with the median 
ICsos as reported in Sheid et al., 2011, Supra. 
Contacts between the antibody light chain and gp120 are 
mostly conserved between the NIH45-46-93THO57 and 
VRC01-93TH-057 structures with a notable exception: 
Ser28was a , in CDRL1 replaces a solvent-exposed tyro 
sine (Tyr28 ) that interacts with ordered N-linked 
carbohydrate attached to ASn2767. By contrast, the 
Ser28was a sidechain does not contact gp120 carbohy 
drates; instead it faces away from gp120, hydrogen bonding 
with Argé4 was as c (FWR3) and creating a 2.7 A dis 
placement of the main-chain Co. atoms (FIG. 11A). The 
Ser28wn as as C-Argó4xtras 46 to interaction is maintained 
in unbound NIH45-46 (FIG. 11B). The position 28 substi 
tution of serine for tyrosine largely accounts for the burial of 
more surface area in gp120’s interaction with the VRCO1 
versus NIH45-46 light chain (681 A versus 395 A total 
buried surface area; 314. A versus 203 A buried surface 
area on the light chain) (Tables 5A, 5B). The larger contact 
area for the VPCO1 light chain may account for the ability 
of VRCO1, but not NIH45-46, to neutralize the Glade C 
CAP45.2.00.G3 strain, given that the NIH45-46 heavy chain 
paired with the VRC01 light chain neutralizes this strain, 
whereas the VRC01 heavy chain paired with the NIH45-46 
light chain does not (Table 12). However, the VRCO1 light 
chain did not increase the potency of NIH45-46 against three 
other viral strains (Table 12), suggesting that the Tyr28 
interaction with gp120 carbohydrate is not obligatory. 
TABLE 12 
In vitro neutralization ICso values mL 
NIH4S- VRCO1 
46 HC HC 
NIH4S- VRCO1 NIH45 
Virus Clade 46 LC 46 LC VRCO1 
AC1O.O.29 B O.9 1.O 4.5 O.8 
TRO.11 B 1.9 O.3 24 O.S 
SC422661.8 B O.OS O.2 0.4 O.2 
QHO692.42 B 0.7 O.9 1.2 0.7 
ZM214.M.PL15.11 C O.S O6 1.8 O.8 
CAP4S.2.OO.G3 C >50 2.1 >50 1.8 
T257-31 CRF02 O.S O6 15 1.O 
(A/G) 
Example 3 
Protein Expression and Purification 
Proteins were produced and purified using previously 
described methods (Diskin et al., 2010, Nat. Struct. Mol. 
Biol., 17:608-613, the entire contents of which are incorpo 
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rated herein by reference). Briefly, NIH45-46 IgG was 
expressed by transient transfection in HEK293-6E cells. 
Secreted IgG was purified from cell Supernatants using 
protein A affinity chromatography (GE Healthcare). Fab 
fragments were prepared by digesting purified IgG with 
immobilized papain (Pierce) at 10 mg/mL and then separat 
ing Fabs from Fc-containing proteins using protein A chro 
matography and Superdex 200 16/60 size exclusion chro 
matography. For crystallization trials, the NIH45-46 Fab for 
crystallization experiments was concentrated to 11 mg/mL 
in 20 mM Tris pH 8.0, 150 mM sodium chloride, 0.02% 
sodium azide (TBS). Substitutions in heavy chain residue 54 
of NIH45-46, 3BNC55, 12A12, 3BNC117 and 3BNC60 
were introduced using a Quikchange II kit (Agilent tech 
nologies). Wild type, mutant forms and chain Swapped 
versions of these proteins were expressed as IgGs in 
HEK293-6E cells and purified by protein A chromatography 
as described for NIH45-46 IgG. Proteins were stored at a 
concentration of 1 mg/mL for neutralization assays in either 
10 mM sodium citrate pH 3.05, 50 mM sodium chloride, 
0.02% sodium azide or in TBS (12A12 and 12A12'') or 
in phosphate buffered saline (NIH45-46 mutated/truncated 
in CDRH3 and NIH45-46/VRC01 heavy and light chain 
swapped antibodies (Abs)) prior to dilution into neutral pH 
cell media. For SPR analyses, NIH45-46 and NIH45-46'' 
heavy chains were subcloned into the pTT5 (NRC-BRI) 
expression vector to encode C-terminal 6x-His tagged Fab 
heavy chains (V-C1-6x-His tag), and the heavy chain 
expression vectors were co-transfected with the appropriate 
light chain vector into HEK293-6E cells. Supernatants were 
collected after 7 days, buffer exchanged into TBS and loaded 
on a Ni"-NTA affinity column (Qiagen). Fabs were eluted 
using TBS supplemented with 2:50 mM imidazole and 
further purified by Superdex200 10/300 size exclusion chro 
matography (GE Healthcare) in TBS. 
Genes encoding truncated 93TH053, CAP244.2.00.D3, 
and Q259.d2.17 gp120 cores including the deletions and 
modifications described in Zhou et al., 2010, supra (the 
entire contents of which are incorporated herein by refer 
ence), were chemically synthesized (BlueHeron). An extra 
disulfide bond was introduced into 93TH053 by changing 
the Val65 and Ser115 codons into cysteines. 
The modified core genes were subcloned into the 
pACgp67b expression vector (BD Biosynthesis) to include 
a C-terminal 6x-His tag, expressed in baculovirus-infected 
insect cells, and purified from insect cell Supernatants as 
previously described in Diskin et al., 2010, Supra. For 
crystallization experiments, purified NIH45-46 Fab and 
93TH057 gp1.20 were incubated at a 1:1 molar ratio and 
treated with 40 kV of Endoglycosidase H (New England 
Biolabs) for 16 hours at 37°C. The complex was purified 
after the incubation by Superdex 200 10/300 size exclusion 
chromatography (GE Healthcare) and then concentrated to 
OD-9.6 in 20 mM Tris pH 8.0, 300 mM sodium chloride, 
0.02% sodium azide. 
Example 4 
Crystallization 
Crystallization screening was done by vapor diffusion in 
sitting drops by a Mosquito(R) crystallization robot (TTP 
labs) using 400 mL drops (1:1 protein to reservoir ratio) 
utilizing commercially available crystallization screens 
(Hampton. Initial crystallization hits for Fab NIH45-46 and 
for NIH45-46-93THO57 complex were identified using the 
PEGRX HTTM (Hampton) screen and then manually opti 
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mized. Thin needle-like crystals of Fab NIH45-46 (space 
group P2,2,2,..., a 49.4 A, b=87.4 A, c=166.4 A; one mol 
ecule per asymmetric unit) were obtained upon mixing a 
protein solution at 11 mg/mL with 12% polyethylene glycol 
20,000, 0.1 M sodium acetate pH 5.0, 0.1 M sodium/ 
potassium tartrate, 0.02 M ammonium sulfate at 20° C. 
Crystals were briefly soaked in mother liquor solution 
supplemented with 15% and then 30% glycerol before flash 
cooling in liquid nitrogen. Crystals of the NIH45-46 
93TH057 complex (space group P222, a-69.1 A, b=70.5 
A, c–217.7 A; one molecule per asymmetric unit) were 
Obtained upon mixing a protein solution at ODs 9.6 with 
12% isopropanol, 10% polyethylene glycol 10,000, 0.1 M 
sodium citrate pH 5.0 at 20° C. Complex crystals were 
cryo-cooled by covering the crystallization drops with par 
affin oil to prevent evaporation and then adding an excess of 
20% isopropanol, 5% glycerol, 10% polyethylene glycol, 
0.1 M sodium citrate pH 5.0 to the drops prior to mounting 
and flash cooling the crystals in liquid nitrogen. 
Example 5 
Data Collection, Structure Solution and Refinement 
X-ray diffraction data were collected at the Stanford 
Synchrotron Radiation Lightsource (SSRL) beamline 12-2 
using a Pilatus 6M pixel detector (Dectris). The data were 
indexed, integrated and scaled using XDS as described in 
Kabsch, 2010, Acta Crystallogr D Biol Crystallogr., 66:125 
132, the entire contents of which are incorporated herein by 
reference. The Fab NIH45-46 structure was solved by 
molecular replacement using Phaser as described in McCoy 
et al., 2007, J. Appl. Cryst., 40:658-674, the entire contents 
of which are incorporated herein by reference, and the VV, 
and C1C, domains of the VRC01 Fab (PDB code 3NGB) 
as separate search models. The model was refined to 2.6 A 
resolution using an iterative approach involving refinement 
using the Phenix crystallography package Adams et al., 
2010, Acta Crystallogr D Biol Crystallogr., 66:213-221, the 
entire contents of which are incorporated herein by refer 
ence, and manually fitting models into electron density maps 
using Coot (Emsley et al., 2004, Acta Crystallogr D Biol 
Crystallogr., 60:2126-2132, the entire contents of which are 
incorporated herein by reference). The final model 
(R =18.4%; R =23.8%) includes 3380 protein atoms, 
125 water molecules and 37 ligand atoms, including 
N-Acetylglucosamine, glycerol and a Sulfate ion (FIG. 2). 
96.5%, 3.3% and 0.2% of the residues were in the favored, 
allowed and disallowed regions, respectively, of the 
Ramachandran plot. The first glutamine of the NIH45-46 
heavy chain was modeled as 5-pyrrolidone-2-carboxylic 
acid. 
A search model fir solving the NIH45-46-93THO57 com 
plex was created by Superimposing the refined structure of 
the NIH45-46 Fab on the VRCO1 Fab in the structure of 
VRC01-93THO57 (PDB code 3NGB). A molecular replace 
ment solution was found as described above using separate 
search models for the VV, domains of NIH45-46 com 
plexed with 93TH057 and the C1C, domains of NIH45-46. (FIG. 2). The complex structure was refined to 2.45 A 
resolution as described for the Fab structure. To reduce 
model bias, the CDRH3 of NIH45-46 was omitted from the 
model and then built into electron density maps after a few 
rounds of refinement. The final model (R-20.7%; 
R=25.6%) includes 5989 protein atoms, 67 water mol 
ecules and 148 atoms of carbohydrates, citrate and chloride 
ions (FIG. 2). 96.1%, 3.5% and 0.4% of the residues were in 
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the favored, allowed and disallowed regions, respectively, of 
the Ramachandran plot. Disordered residues that were not 
included in the model were residues 1-2 of the NIH45-46 
light chain, residues 133-136 and 219-221 of the heavy 
chain, and residues 302-308 (V3 substitution), residues 
397-408 (a total of 6 residues from V4) and the 6x-His tag 
of 93TH057. The first glutamine of the NIH45-46 heavy 
chain was modeled as 5-pyrrolidone-2-carboxylic acid. 
Buried surface areas were calculated using AreaIMol in 
CCP4 and a 1.4. A probe. Superimposition calculations were 
done and molecular representations were generated using 
PyMol (The PyMOL Molecular Graphics System, 
Schrödinger, LLC). 
Example 6 
Surface Plasmon Resonance (SPR) Measurements 
The binding of gp120 core proteins to wild-type NIH45 
46 Fab and to mutant (NIH45-46''') Fab was compared 
using a Biacore T100 instrument (GE Healthcare). Purified 
NIH45-46 and NIH45-46'' Fabs were immobilized at 
coupling densities of 500 resonance units (RU) or 1500 RU 
on a CM5 sensor chip (Biacore) in 10 mM acetate pH 5.0 
using primary amine coupling chemistry as described in the 
Biacore manual. One of the four flow cells on each sensor 
chip was mock-coupled using buffer to serve as a blank. 
Experiments were performed at 25° C. in 20 mM HEPES, 
7.0, 150 mM sodium chloride and 0.005% (v/v) surfactant 
P20, and the sensor chips were regenerated using 10 mM 
glycine, 2.5. gp120 core proteins were injected in a two-fold 
dilution series at concentrations ranging from 500 nM to 
31.2 nM at a flow rate of 70 uL/min. After subtracting the 
signal from the mock-coupled flow cell, kinetic data were 
globally fit to a 1:1 binding model (Biacore evaluation 
software) to derive on- and off-rate constants, which were 
used to calculate affinities as Kok/k. 
Example 7 
In Vitro Neutralization Assays 
A previously-described pseudovirus neutralization assay 
was used to compare the neutralization potencies of wild 
type and mutant IgGs as previously described in Montefiori, 
2005, Current protocols in immunology, Edited by John E. 
Coligan et al., Chapter 12, Unit 12.11, the entire contents of 
which are incorporated herein by reference. Briefly, 
pseudoviruses were generated in HEK293T cells by co 
transfection of an EnV-expressing vector and a replication 
incompetent backbone plasmid. Neutralization was assessed 
by measuring the reduction in luciferase reporter gene 
expression in the presence of a potential inhibitor following 
a single round of pseudovirus infection in TZM-bl cells. 
Antibodies were pre-incubated with 250 infectious viral 
units in a three or four-fold dilution series for one hour at 37° 
C. before adding 10,000 TZM-bl cells per well for a two-day 
incubation. Cells were then lysed and luciferase expression 
was measured using BrightGlo (Promega) and a Victor3 
luminometer (PerkinElmer). Nonlinear regression analysis 
using the program Prism (GraphPad) was used to calculate 
the concentrations at which half-maximal inhibition was 
observed (ICs values) as described in Klein et al., 2009, 
PNAS, 106.7385-7390, the entire contents of which are 
incorporated herein by reference. Samples were initially 
screened in duplicates. Reagents that showed enhanced 
activity were tested again as triplicates. Values for NIH45-46 
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and NIH45-46'' in FIG. 14 were obtained from three 
independent experiments. Similar ICs values were obtained 
in two independent neutralization experiments using differ 
ent dilution series. 
Example 8 
Signature Features of ITT Antibodies 
The correlation between neutralization potency and the 
length of two of the light chain CDR, loops was analyzed in 
CD4bs antibodies. The relatively small CDRL1 of VRC01, 
which has a 2-residue deletion relative to its germline 
precursor, was previously correlated with increased neutral 
ization potency (Zhou et al., 2010, supra). It was noted that 
sequences of VRC01, NIH45-46, and VRC-PG04 revealed 
a more striking correlation for the length of CDRL3, which 
is only 5 residues in these antibodies. Examination of the 
large Abysis database for human Ab sequences (http:// 
www.bioinforg.uk/abs/) showed that only about 1% of V, 
domains have a CDRL3 length of 5 amino acids, compared 
with more typical 9-11 residue lengths. Larger CDRL3 loops 
would place critical side chains at the tip of CDRL3 in 
different locations, thus notable to interact with gp120 in the 
same manner. In antibodies with longer CDRL3s, the tip of 
CDRL3 interacts with Trp47, a highly conserved residue (found in 63 of 69 germline V gene segments) that plays a 
similar role as Trp 102, in the Abs with 5-residue CDRL3s 
to stabilize the V-V, interface. 
V domain alignments revealed the following sequence 
characteristics of the most potent of the VRC01-like Abs: 
complete conservation of heavy chain Arg71, Trp50, 
ASn58, and Trp102, and light chain Glu90, Trp65/ 
Phe65, and a CDRL3 length of exactly 5 amino acids 
(residues are numbered here as in the structure of NIH45-46; 
pdb code 3U7Y). Analysis of the per residue variability of 
VH1-2*02-derived Abs indicates that the conservation of 
Trp50, and Asni58, is unlikely to be coincidental. 
The roles that conserved residues play in the V domain 
structure and in binding to the CD4bs on gp1.20 are shown 
schematically in FIG. 16 and Table 13, below. The figures 
are based on interactions present in the gp120 complexes of 
VRC01, NIH45-46, and VRC-PG04 (Wu et al., 2011, Sci 
ence, 333:1593-1602: Diskin et al., 2011, Science, 334: 
1289-1293; and Zhou et al., 2010, Science, 329:811-817, the 
entire contents of all of which are incorporated herein by 
reference. 
TABLE 13 
PWL. Features 
PVL Characteristic feature Role 
Trp50. H bond with ASn280io 
ASn58. H bond with Arg456,120 
Arg71 to H bond/salt bridge with Asp368 120 
Trp102 H bond with ASn/Asp279,120 
Glu90**, H bond with Gly459.20 
Trp65***/ interaction with ASn276,120 glycan 
Pheg5***, 
5-residue. CDRL3 prevent steric clashes, position 89 & 
90 side chains 
*Position Trp100B; 
**Postion Glu96; and 
***Trp67 Phe67 using Kabat numbering system. 
The side chains of Trp50, Trp102, and Trp47, form 
an unusual propeller-like arrangement on the Surface the V 
domain. (Although Trp47 participates in the “propeller.” 
it is not considered to be a signature residue of potent CD4bs 
antibodies because it is commonly found in V, domains). 
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The main interactions of the characteristic V. domain resi 
dues with gp120 are as follows: Trp50: indole N H 
hydrogen bonds with the side chain oxygen of ASn2802: 
Asni58: side chain N H hydrogen bonds with the back 
bone carbonyl of Arg4562: Arg71: side chain hydro 
gen bonds/salt bridges with the side chain of Asp3682: 
and Trp 102: indole N H hydrogen bonds with the side 
chain oxygen of ASn/Asp2792. Trp102, also buries 85 
A of surface area at the V/V, interface—contacting resi 
dues Tyr89, and Glu90,. 
In the light chains, the side chain of Glu90, forms a 
hydrogen bond with the backbone nitrogen of Gly459 gp120 
and/or the side chain of ASn28020. The conservation of 
Trp65/Phe65, is surprising as this position is distant 
from gp120 in the available crystal structures. 
For those interactions that depend on specific gp120 side 
chains, the degree of conservation of the relevant gp120 
residues is 96.4% for Asn/Asp2792, 96.4% for 
ASn280 and 99.7% for Asp368 (based on the 2010 gp120 
filtered web alignment of 2869 HIV-1 sequences in the Los 
Alamos HIV database: http://www.hiv.lanl.gov/). 
Arg4562, which is involved in a main-chain hydrogen 
bond with the sidechain of ASn58, is also highly con 
served (95.0%). 
An SPR-based binding assay demonstrated detectable 
binding of the germline heavy chain/mature light chain IgG 
to immobilized gp140 trimers. Binding of germline heavy 
chain IgGs was analyzed with Substitutions in the four 
signature heavy chain residues (W50S, N58S, R71T, and 
W102S) (again paired with the mature 3BNC60 light chain). 
The W50S, R71T, and W102S mutants showed little or no 
gp140 binding, and the N58S mutation diminished binding 
by about 20-fold, consistent with the corresponding PVL 
characteristic residues playing key roles in recognition of the 
HIV-1 envelope spike by the germline PVL B cell receptor. 
To examine the importance of the signature PVL residues 
to their activity, the gp120 sequences of HIV-1 strains 
resistant to neutralization by NIH45-46 were analyzed. The 
gp120 residue variants associated with resistance were iden 
tified by three criteria: first, they are contact residues with 
NIH45-46; second, they are absent in NIH45-46-resistant 
viruses; third, they do not appear in NIH45-46-sensitive 
viruses. The critical positions identified were 2792. 
28020, 4562o. 458,120, and 459.20, the common (i.e. sensitive) residues at these positions are ASX, ASn, Arg, 
Gly, and Gly, respectively, where ASX is Asp or Asn. These 
sites make significant contacts with the characteristic PVL 
residues (FIG. 16). Viral stains with variations at these sites 
are generally neutralized poorly by all PVL antibodies, as 
expected if substitutions at these positions interfere with 
common interactions. 
To verify the significance of gp120 variations at these 
positions, point mutants within the gp160 gene of HIV-1 
strain YU2 were engineered, created pseudoviruses carrying 
the mutant gp160s, and determined the neutralization poten 
cies of the PVL NIH45-46'' (Diskin et al., 2011, supra) 
(as characterized by ICso values). Mutations at 2792 and 
280, rendered the virus resistant to neutralization by 
NIH45-46'', and substitution of 458,120 diminished the 
neutralization potency by >1500-fold (FIG. 17). 
Example 9 
Neutralization of NIH45-46 Resistant HIV Strains 
with 45-46 m2 Antibody 
In an effort to increase the breadth of NIH45-46'', a 
S28Y substitution was introduced into the light chain of the 
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TABLE 14-continued 
IC 
Virus ID Clade NIH45-46 NIH45-46' 45-46m2 
6244 13 B5 4576 B (T/F) O.O7 O.OOS 
CNE19 BC O.O7 O.OO2 
BJOXO28OOO.10.3 CRF01. AE (TIF) 0.07 O.OO1 
X1632 S2 B10 G O.O7 Not Tested 
BJOXO1 SOOO.11.5 CRF01. AE (TIF) 0.06 O.048 
SC422661.8 B O.O6 O.O2 
62357 14 D3 4589 B (T/F) O.O6 O.O2 
WITO416O.33 B O.O6 O.O1 
Ce2O60 G9 C (T/F) O.OS8 O.OOS 
Ce0682 E4 C (T/F) O.OS4 O.O1 
231965.c)1 D O.OS1 O.OO1 
263-8 CRFO2 AG O.OS O.OO1 
Q259.d2.17 A. O.043 O.OO1 
Ce1086 B2 C (T/F) O.04 O.019 
TRO4S51.58 B O.04 O.O1 
249MB10 C (T/F) O.04 O.OO1 
6811.wf.c18 CD O.O3S O.OO1 
R2184c04 CRFO1 AE O.O34 O.OOS 
6480.wa.c25 CD O.O32 O.004 
X1254 c3 G O.O32 O.OO2 
Q842.d 12 A. O.O31 O.OOS 
CNE52 BC O.O3 O.O1 
AO7412M1.wrc12 D O.O3 O.OO 
3365.w2.c2 A. O.O29 O.O1 
C3347.c11 CRFO1 AEB O.O29 O.OO 
1006 11 C3 1601 B (T/F) O.O27 O.OO 
3415.w1.c1 A. O.O22 O.OO 
X1193 c1 G O.O21 O.OO 
6952.w1.c2O CD O.O2 O.OO 
Du156.12 C O.O2 O.OO 
HIV-16OSS-23 C O.O2 O.OO 
191084 B7-19 A (T/F) O.O2 O.OO 
ZM249M.PL.1 C O.O17 O.OO2 
RHPA4259.7 B O.O17 O.OO 
REJO4S41.67 B O.O14 O.OO2 
O815.w3.c3 ACD O.O14 O.OO 
HIV-OO13095-2.11 C O.O1 O.OOS 
BF1266.431a. C (T/F) O.O1 O.OO 
1012 11 TC21 3257 B (T/F) O.O1 O.OO 
Q769.d22 A. O.OO9 O.OO 
3301 w1.c24 AC O.OO9 O.OO 
CNE53 BC O.OO8 O.OO 
6041.w3.c23 AC O.OO6 O.OO 
WEAU d15 410 787 B (T/F) O.OOS O.OO 
HIV-001428-242 C O.OO1 O.OO 
O26Ows.c36 A. NT O. 117 
CNE8 CRFO1 AE NT 0.055 
Against the panel of viruses listed in Table 14, 45-46 m2 
antibody was as potent as NIH45-46'' (geometric mean 
ICso values of 0.028 ug/ml and 0.030 lug/ml for 45-46 m2 
and NIH45-46'', respectively), but exhibited increased 
breadth as shown graphically in FIG. 18, neutralizing up to 
96% of strains. Specifically, as shown in FIG. 18, the 45-46 
m2 antibody was tested along with NIH45-46 and NIH45 
46'' in neutralization assays against the CAVD strain 
panel and showed overall improvement across these strains 
compared to NIH45-46 and NIH45-46''. The first 28 
strains of Table 14 above were either poorly neutralized 
(ICsa1.0 ug/ml) by NIH45-46 or were NIH45-46-resistant 
(ICs >50 lug/ml). However, the 45-46 m2 antibody showed 
improved neutralization and had a geometric mean ICso of 
0.35 ug/ml compared with geometric means of 1.84 ug/ml 
for NIH45-46'' and 14.51 ug/ml for NIH45-46. For Table 
14, ICsos greater than 50 lug/ml are shown as 50 ug/ml. 
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As shown in FIGS. 19 and 20A-20I, the neutralizing 
activity of NIH45-46'' was compared to the neutralizing 
activity of 45-46 m2 using viruses from an “elite neutral 
izer.” patient VC10042, who developed unusually broad and 
potent cross-neutralizing antibody responses, but whose 
circulating viruses evolved to escape their action. With few 
exceptions, the viral clones isolated from VC10042 were 
highly resistant to known bNAbs, especially CD4bs anti 
bodies (Sather, D.N. et al. J Virol (2012), the entire contents 
of which are herein incorporated by reference.) Only 1 viral 
done isolated from VC10042 was susceptible to VRC01, but 
the majority (8 of 12) were moderately susceptible to 
NIH45-46''. By contrast, NIH45-46 m2 neutralized all 
(12 of 12) of the viral clones with up to 10-fold increased 
6' when evaluated potency compared with NIH45-4 
against NIH45-46'-sensitive clones as shown in the 
neutralization graph of FIGS. 19 and 20A-20I, and the ICso 
data in Table 15 below. 
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TABLE 15-continued 
IC 
Virus ID Virus ID NIH45-46 NIH45-46' 45-46m2 
WITO416O.33 B O.26 O.04 O.O73 
P1981 C5 3 G O.24 O.O7 O.O45 
P0402 c2 .11 G O.214 O.O23 O.042 
1006 11 C3 1601 B (T/F) O.196 O.OO8 O.O37 
62357 14 D3 4589 B (TIF) O.19 O.O7 O.O84 
249MB10 C (T/F) O.17 O.019 O.O17 
Ce0682 E4 C (T/F) 0.155 O.O39 O.O31 
Q259.d2.17 A. O.154 O.O14 O.O11 
SC422661.8 B O.13 O.O7 O.09 
TRO4S51.58 B O.13 O.OS O.O2 
AO7412M1.wrc12 D O.13 O.042 O.064 
R2184c04 CRFO1 AE O.127 O.036 O.O39 
231965.c)1 D O.126 O.O3S O.O3S 
CNE52 BC O.12 O.OS2 O.O28 
6811.wf.c18 CD O. 113 O.O33 O.11 
3365.w2.c2 A. O.11 O.OS6 O.049 
X1254 c3 G O.107 O.018 O.O3 
263-8 CRF02 AG O. O.O2S OO67 
6480.wa.c25 CD O. O.O21 O.OS8 
C3347.c11 CRFO1 AE O.O94 O.O28 O.O34 
3415.w1.c1 A. O.O86 O.O23 O.OS4 
Q842.d 12 A. O.O73 O.O2S O.O17 
91084 B7-19 A (T/F) O.O7 O.O26 O.O16 
6952.w1.c2O CD O.O7 O.O1 O.042 
X1193 c1 G O.O64 O.O09 O.OS4 
HIV-16OSS-23 C O.O6 O.O24 O.O17 
Du156.12 C O.OS4 O.OOS O.O24 
ZM249M.PL.1 C O.OS3 O.007 O.O17 
O815.w3.c3 ACD O.OS2 O.OO3 O.OO)4 
RHPA4259.7 B O.O47 O.007 O.OO7 
012 11 TC21 3257 B (T/F) O.04 O.OO3 O.OO8 
6041.w3.c23 AC O.04 O.OO1 O.OO3 
CNE53 BC O.O39 O.OOS O.O39 
REJO4S41.67 B O.O3S O.O13 O.O1 
Q769.d22 A. O.O33 O.O09 O.O17 
3301 w1.c24 AC O.O33 O.004 O.OO6 
HIV-OO13095-2.11 C O.O3 O.O27 O.O17 
BF1266.431a C (T/F) O.O3 O.OO1 O.O13 
WEAU d15 410 787 B (TIF) O.O15 O.OO3 O.O27 
HIV-OO1428-242 C O.O1 O.OO1 O.OO2 
O26Ows.c36 A. Not Tested O.399 O.O84 
CNE8 CRFO1 AE Not Tested O.24 O.156 
Example 10 were further purified using Superdex 200 (from GE Health 
Vector Construction, Protein Expression and 
Protein Purification 
Modifications of NIH45-46 heavy and light chain genes 
were made using QuikChange Lightning (from Agilent 
Technologies) and verified by DNA sequencing (from Eton 
Bioscience). Antibodies were expressed as IgGs using 
described protocols (Diskin et al., 2010Nat. Struct. Mol. 
Biol., 17:608-613, the entire contents of which are incorpo 
rated herein by reference), Briefly, secreted IgGs from 
polyethyleneimine (25 kD, linear; from Polysciences)— 
mediated, transiently-transfected HEK293-6E cells were 
captured on a protein A affinity column (from GE Health 
care) and eluted in 100 mM citrate pH 3.0, 150 mM sodium 
chloride. Antibodies Subsequently used in neutralization 
assays were dialyzed into 10 mM citrate pH 3.0, 150 mM 
Sodium chloride and adjusted to a concentration of 1 mg/ml. 
Fab fragments for crystallization and binding assays were 
obtained by digesting IgGs in 20 mM Tris pH 8.0, 150 mM 
sodium chloride (TBS) with a 1:100 ratio of papain (from 
Sigma) activated in 50 mM phosphate 7.0, 2 mMethylene 
diaminetetraacetic acid, 10 mM cysteine at 37° C. until 
completion of the cleavage (20 min-60 min). The digested 
IgGs were then analyzed by SDS-PAGE. The Fc fragment of 
the IgG was removed by protein A chromatography and Fabs 
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care) 10/300 Size Exclusion Chromatography (SEC). 
The Glade A/E 93TH057-derived gp120 core (a gp120 
construct lacking the V1/V2 and V3 loops) was expressed in 
insect cells and purified as described in Diskin et al., 2011. 
Supernatants from baculovirus-infected insect cells were 
collected, buffer exchanged into TBS and passed through a 
Ni"-NTA affinity column (from GE Healthcare). gp120 was 
eluted from the column using TBS plus 250 mM imidazole 
and purified using Superdex 200 16/60 SEC (from GE 
Healthcare) in TBS supplemented with 0.02% (w/v) sodium 
azide. 
Example 11 
Neutralization Assays 
A pseudovirus neutralization assay was used to assess the 
neutralization potencies of the various antibodies against 
multiple HIV strains, as described in Montefiori, D.C. Cur 
rent protocols in Immunology, edited by John E. Coligan 
Chapter 12, Unit 12 11 (2005), the entire contents of which 
are herein incorporated by reference. In all cases, neutral 
ization was monitored by the reduction of a Tat-induced 
reporter gene (luciferase) in the presence of a three- or 
five-fold antibody dilution series (each concentration run in 
duplicate or triplicate) after a single round of pseudovirus 
infection in a TZM-bl cell line as described in Montefiori, 
previously incorporated by reference herein. Antibodies 
were incubated with 250 viral infectious units at 37° C. for 
US 9,493,549 B2 
43 
one hour prior to incubation with the reporter cells (10,000 
per well) for 48 hours. Luciferase levels were measured 
from a cell lysate using BrightGloTM (from Promega) and a 
Victor3TM luminometer (from PerkinElmer). Data were fit 
by Prism (from GraphPad) using nonlinear regression to find 
the concentration at which 50% inhibition occurred (i.e., 
ICso value). 
Example 12 
Neutralization Assay of 3BNC50. Mutants 
The Phe-43 equivalent position in 3BNC50 is threonine at 
position 54. This threonine was substituted with one of the 
19 amino acids listed in Tables 16 and/or 17, and assayed in 
a neutralization assays against the viral Strains including 
SC422661.8, TRO. 11, CAP45.2.00G3, CAP210.2.00E8, 
Du172.17, and AC10.0.29. 
ICso results averaged across the strains are shown below 
in Table 16. The substitutions shown in Table 16 show an 
average improvement overall the tested Strains. Specifically, 
5 
10 
15 
44 
even though certain Substitutions may show higher ICso 
values than the wild type for specific strains, the substitu 
tions reported in Table 16 have ICs values averaged over all 
strains that are lower than the wild type. Table 17 shows the 
individual ICso values of the listed substitutions for the 
specific strains. 
TABLE 16 
HCSubstitution ICso 
TS4G O.O3 
TS4H O.04 
TS4A O.14 
T54Q O.14 
TS4R O.17 
T54Y O.2O 
T54N O.22 
T54W O.25 
T54F O.25 
WT(T54) O.30 
TABLE 17 
ICso data for the indicated 3BNC60 mutants in 6 viral Strains. 
3BNC6O SC42266.1.8 
SEQUENCE LISTING SEO ID NOS; 
Light Chain 
Antibody Name SEQ ID NO : 
WRCO1 1. 
EIVILTOSPGTLSLSPGETAIISCRTSQYGSLAWYOORPGQAPRLVI 
YSGSTRAAGIP 
45 
50 
55 
TRO.11 CAP4S.2.OO.G3 CAP210.2.OO.E8 D172.17 AC1O.O.29 
O.018 43.176 10.6 14OO >SO 
O.OO3 >50 O.1 >50 2.6 
O.OO)4 >50 >50 >50 2.92 
O.OOO3O >50 11.9 O.O2 O.623 
O.OO6 >50 S.O 2.15 >50 
O.036 >50 >50 >50 >50 
O.OO8 16.7 16.3 O.662 >SO 
O.OO6 6.66 7.4 O.243 9.04 
O.O11 6.64 1.6 0.055 >50 
O.O29 >50 >50 >50 >50 
O.O2O 41.7 14.7 O.92 >SO 
O.O27 >50 >50 21.8 >50 
O.O24 >50 42.8 7.36 >50 
O.019 >50 30.7 3.59 >50 
O.019 >50 2S.O 1.43 >SO 
O.048 >50 >50 >50 >50 
O.O21 ND 2.6 2.2 ND 
O.O12 ND 2.9 2.2 ND 
O.O23 ND 3.4 2.2 ND 
As disclosed throughout, a PVL antibody such as NIH45 
46, Substituted at the Phe-A3-equivalent residue (position 
54) with a heavy chain substitution selected from a hydro 
phobic amino acid, glycine, histidine, arginine, glutamine, 
asparagine, lysine, glutamic acid, and aspartic acid, has 
increased potency and breadth in HIV strains. Furthermore, 
including a second, light chain Substitution of serine at 
position 28 of the light chain with tyrosine yields an even 
greater increase in potency and breadth in HIV strains. 
While the present invention has been illustrated and 
described with reference to certain exemplary embodiments, 
those of ordinary skill in the art will understand that various 
modifications and changes may be made to the described 
embodiments without departing from the spirit and scope of 
the present invention, as defined in the following claims. 
1 - 46 
Heavy Chain 
SEQ ID NO: 
2 
QVOLVOSG-- 
GQMKKPGESMRISCRASG- - - 




Antibody Name 
< 16 Os 
PRT 
<4 OOs, SEQUENCE: 
Glu 
1. 
Glu 
Trp 
Gly 
Trp 
65 
Phe 
Ile Wall Lieu 
Thir 
Ser 
SO 
Gly 
Gly 
Wall 
Ala 
Glin 
35 
Thir 
Pro 
Wall 
Glin 
Ile 
Glin 
Arg 
Asp 
Tyr 
Wall 
1OO 
Light Chain 
53 
SEO ID NO: 
19 
SEQ ID NO 1 
LENGTH: 
TYPE : 
ORGANISM: 
104 
NUMBER OF SEO ID NOS: 46 
Homo sapiens 
1. 
Thir 
Ile 
Arg 
Ala 
Tyr 
Tyr 
85 
Asp 
<210s, SEQ ID NO 2 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Homo sapiens 
PRT 
<4 OOs, SEQUENCE: 
49 
2 
Glin 
Ser 
Pro 
Ala 
Asn 
70 
Ile 
Ser 
Gly 
Gly 
55 
Lell 
Glin 
Pro 
Arg 
Glin 
4 O 
Ile 
Thir 
Glin 
Arg 
Glin Val Glin Leu Val Glin Ser Gly 
1. 5 
Ser Met Arg Ile Ser Cys Arg Ala 
Thir Lieu. Asn Trp Ile Arg Lieu Ala 
Gly 
< 4 OOs 
35 
PRT 
SEQUENCE: 
SEQ ID NO 3 
LENGTH: 
TYPE : 
ORGANISM: Homo sapiens 
104 
3 
4 O 
Gly 
Thir 
25 
Ala 
Pro 
Ile 
Gly 
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SEOUENCE LISTING SE 
Thir 
Ser 
Pro 
Asp 
Ser 
Glu 
90 
Luell 
Glin 
Arg 
Arg 
ASn 
Phe 
SEQUENCE LISTING 
Ser 
Lell 
Phe 
6 O 
Lell 
Phe 
Gln Met Lys 
Ser Gly Tyr Glu 
25 
Pro Gly Lys Arg 
Lell 
Gly 
Wall 
45 
Ser 
Glu 
Gly 
Lys 
Phe 
Pro 
45 
Ser 
Ser 
Ile 
Gly 
Ser 
Glin 
ID NOS 
Pro 
15 
Luell 
Ser 
Gly 
Gly 
95 
Gly 
Ala 
Ser 
Arg 
Asp 
Thir 
Pro Gly Glu 
15 
Ile Asp Cys 
Glu Trp Met 
1 - 46 
54 
Heavy Chain 
SEO ID NO : 
46 
QVOLVOSGSAMKKP 
GASWRWSCWTSEDIF 
DTTELIHWVROAPGO 
GLEWIGWWKAWSGA 
WNYGSLDFRHRWSLT 
RDRDLSTAHMDIRGL 
TODDTATYFCAROK 
FARGDOGWFFDLWG 
RGTLIWWSSA 
55 
Glu Ilie Wall Lieu. Thir Glin Ser Pro 
Glu Thir Ala Ile Ile Ser Cys Arg 
2O 
Trp Tyr Glin Glin Arg Pro Gly Glin 
35 4 O 
Gly Ser Thr Arg Ala Ala Gly Ile 
SO 55 
Trp Gly Pro Asp Tyr Asn Lieu. Thr 
65 70 
Phe Gly Lieu. Tyr Tyr Cys Glin Glin 
85 
Llys Val Glin Val Asp Ile Lys Arg 
1OO 
<210s, SEQ ID NO 4 
&211s LENGTH: 121 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 4 
Glin Val Glin Leu Val Glin Ser Gly 
1. 5 
Ser Met Arg Ile Ser Cys Glin Ala 
2O 
Thir Lieu. Asn Trp Val Arg Lieu Ala 
35 4 O 
Gly Trp Lieu Lys Pro Arg Gly Gly 
SO 55 
Gln Gly Arg Val Thr Met Thr Arg 
65 70 
Lieu. Glu Lieu. Arg Ser Lieu. Thir Ala 
85 
Thir Arg Gly Lys Asn. Cys Asp Tyr 
1OO 
Arg Gly Thr Pro Val Thr Val Ser 
115 12 O 
<210s, SEQ ID NO 5 
&211s LENGTH: 107 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 5 
Glu Ilie Wall Lieu. Thir Glin Ser Pro 
1. 5 
Glu Thir Ala Ile Ile Ser Cys Arg 
2O 
Trp Tyr Glin Glin Arg Pro Gly Glin 
35 4 O 
Gly Ser Thr Arg Ala Ala Gly Ile 
SO 55 
Trp Gly Ala Asp Tyr Asn Lieu. Ser 
65 70 
Phe Gly Val Tyr Tyr Cys Glin Glin 
85 
Gly 
Thir 
25 
Ala 
Pro 
Ile 
Gly 
Ser 
25 
Pro 
Ala 
Asp 
Asp 
Asn 
105 
Ser 
Ala 
Thir 
25 
Ala 
Pro 
Ile 
Thir 
Ser 
Pro 
Asp 
Arg 
Glu 
90 
Glin 
Gly 
Gly 
Wall 
Wall 
Asp 
90 
Trp 
Thir 
1O 
Ser 
Pro 
Asp 
Ser 
Glu 
90 
Luell 
Glin 
Arg 
Arg 
ASn 
Phe 
Met 
Tyr 
Arg 
ASn 
Tyr 
Thir 
Asp 
Luell 
Glin 
Arg 
Arg 
ASn 
Phe 
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Ser Leu Ser Pro Gly 
15 
Tyr Gly Ser Lieu Ala 
3O 
Lieu Val Ile Tyr Ser 
45 
Phe Ser Gly Ser Arg 
6 O 
Lieu. Glu Ser Gly Asp 
8O 
Phe Gly Glin Gly Thr 
95 
Llys Llys Pro Gly Glu 
15 
Glu Phe Ile Asp Cys 
3O 
Arg Pro Glu Trp Met 
45 
Tyr Ala Arg Pro Lieu. 
6 O 
Ser Asp Thr Ala Phe 
8O 
Ala Val Tyr Tyr Cys 
95 
Phe Glu. His Trp Gly 
11 O 
Ser Leu Ser Pro Gly 
15 
Ser Gly Ser Lieu Ala 
3O 
Lieu Val Ile Tyr Ser 
45 
Phe Ser Gly Ser Arg 
6 O 
Lieu. Glu Ser Gly Asp 
8O 
Phe Gly Glin Gly Thr 
95 
56 
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Llys Val Glin Val Asp Ile Lys Arg Thr Val Ala 
1OO 105 
<210s, SEQ ID NO 6 
&211s LENGTH: 125 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 6 
Glin Val Arg Lieu. Ser Glin Ser Gly Gly Glin Met Lys Llys Pro Gly Glu 
1. 5 1O 15 
Ser Met Arg Lieu. Ser Cys Arg Ala Ser Gly Tyr Glu Phe Lieu. Asn. Cys 
2O 25 3O 
Pro Ile Asn Trp Ile Arg Lieu Ala Pro Gly Arg Arg Pro Glu Trp Met 
35 4 O 45 
Gly Trp Lieu Lys Pro Arg Gly Gly Ala Val Asn Tyr Ala Arg Llys Phe 
SO 55 6 O 
Gln Gly Arg Val Thr Met Thr Arg Asp Val Tyr Ser Asp Thr Ala Phe 
65 70 7s 8O 
Lieu. Glu Lieu. Arg Ser Lieu. Thir Ser Asp Asp Thr Ala Val Tyr Phe Cys 
85 90 95 
Thir Arg Gly Lys Tyr Cys Thr Ala Arg Asp Tyr Tyr Asn Trp Asp Phe 
1OO 105 11 O 
Glu. His Trp Gly Arg Gly Ala Pro Val Thr Val Ser Ser 
115 12 O 125 
<210 SEQ ID NO 7 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OO > SEQUENCE: 7 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Arg Val Gly 
1. 5 1O 15 
Asp Thr Val Thir Ile Thr Cys Glin Ala Asn Gly Tyr Lieu. Asn Trp Tyr 
2O 25 3O 
Glin Glin Arg Arg Gly Lys Ala Pro Llys Lieu. Lieu. Ile Tyr Asp Gly Ser 
35 4 O 45 
Llys Lieu. Glu Arg Gly Val Pro Ala Arg Phe Ser Gly Arg Arg Trp Gly 
SO 55 6 O 
Glin Glu Tyr Asn Lieu. Thir Ile Asn. Asn Lieu. Glin Pro Glu Asp Wall Ala 
65 70 7s 8O 
Thr Tyr Phe Cys Glin Val Tyr Glu Phe Ile Val Pro Gly Thr Arg Lieu. 
85 90 95 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 8 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 8 
Glin Val His Lieu. Ser Glin Ser Gly Ala Ala Val Thr Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glu Ala Ser Gly Tyr Lys Ile Ser Asp His 
2O 25 3O 
Phe Ile His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glin Trp Val 
58 
59 
35 4 O 
Gly Trp Ile Asin Pro Llys Thr Gly 
SO 55 
Glin Gly Arg Val Ser Lieu. Thir Arg 
65 70 
Tyr Ser Phe Tyr Met Asp Leu Lys 
85 
Ile Tyr Phe Cys Ala Arg Glin Arg 
1OO 
Trp Gly Ser Gly Thr Glin Val Thr 
115 12 O 
<210s, SEQ ID NO 9 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 9 
Asp Ile Gln Met Thr Glin Ser Pro 
1. 5 
Asp Thr Val Thir Ile Thr Cys Glin 
2O 
Glin Glin Arg Arg Gly Lys Ala Pro 
35 4 O 
Llys Lieu. Glu Arg Gly Val Pro Ser 
SO 55 
Glin Glu Tyr Asn Lieu. Thir Ile Asn 
65 70 
Thr Tyr Phe Cys Glin Val Tyr Glu 
85 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 10 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 10 
Glin Val Glin Lieu. Lieu. Glin Ser Gly 
1. 5 
Ser Val Arg Val Ser Cys Glu Ala 
2O 
Phe Ile His Trp Trp Arg Glin Ala 
35 4 O 
Gly Trp Ile Asin Pro Llys Thr Gly 
SO 55 
Glin Gly Arg Val Ser Lieu. Thir Arg 
65 70 
Phe Ser Phe Tyr Met Asp Leu Lys 
85 
Val Tyr Phe Cys Ala Arg Glin Arg 
1OO 
Trp Gly Ser Gly Thr Glin Val Thr 
115 12 O 
Glin 
Glin 
Ala 
Ser 
105 
Wall 
Ser 
Ala 
25 
Arg 
Asn 
Phe 
Ala 
Ser 
25 
Pro 
Glin 
His 
Ala 
Ser 
105 
Wall 
Pro 
Ala 
Wall 
90 
Asp 
Ser 
Ser 
Asn 
Luell 
Phe 
Luell 
Wall 
90 
Ala 
Gly 
Gly 
Pro 
Ala 
Luell 
90 
Asp 
Ser 
ASn 
Ser 
Arg 
Phe 
Ser 
Luell 
Gly 
Luell 
Ser 
Glin 
Wall 
Wall 
Tyr 
Glin 
ASn 
Ser 
7s 
Arg 
Ser 
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Asn 
6 O 
Trp 
Ser 
Trp 
Ser 
Tyr 
Ile 
Gly 
6 O 
Pro 
Pro 
Thir 
Asn 
Gly 
Asn 
6 O 
Trp 
Ser 
Trp 
45 
Pro 
Asp 
Asp 
Asp 
Ala 
Lell 
Tyr 
45 
Arg 
Glu 
Gly 
Ile 
Lell 
45 
Pro 
Asp 
Asp 
Asp 
Arg 
Phe 
Asp 
Phe 
11 O 
Ser 
Asn 
Asp 
Arg 
Asp 
Thir 
Pro 
Arg 
Glin 
Arg 
Phe 
Asp 
Phe 
11 O 
Glin 
Asp 
Thir 
95 
Asp 
Wall 
15 
Trp 
Gly 
Trp 
Ile 
Arg 
95 
Gly 
15 
Asp 
Trp 
Glin 
Asp 
Thir 
95 
Asp 
Phe 
Thir 
8O 
Ala 
Wall 
Gly 
Ser 
Gly 
Ala 
Luell 
Ala 
Wall 
Phe 
Thir 
8O 
Ala 
Wall 
60 
US 9,493,549 B2 
61 
- Continued 
<210s, SEQ ID NO 11 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 11 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Arg Val Gly 
1. 5 1O 15 
Asp Thr Val Thir Ile Thr Cys Glin Ala Asn Gly Tyr Lieu. Asn Trp Tyr 
2O 25 3O 
Glin Glin Arg Arg Gly Lys Ala Pro Llys Lieu. Lieu. Ile Tyr Asp Gly Ser 
35 4 O 45 
Lys Lieu. Glu Thr Gly Val Pro Ser Arg Phe Thr Gly Arg Arg Trp Gly 
SO 55 6 O 
Glin Glu Tyr Asn Lieu. Thir Ile Asn. Asn Lieu. Glin Pro Glu Asp Ile Ala 
65 70 7s 8O 
Thr Tyr Phe Cys Glin Val Tyr Glu Phe Ile Val Pro Gly Thr Arg Lieu. 
85 90 95 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 12 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 12 
Gln Val Arg Lieu Lieu. Glin Ser Gly Ala Ala Val Thr Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glu Ala Ser Gly Tyr Glu Ile Arg Asp Tyr 
2O 25 3O 
Phe Ile His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glin Trp Val 
35 4 O 45 
Gly Trp Ile Asin Pro Llys Thr Gly Glin Pro Asn Asn Pro Arg Glin Phe 
SO 55 6 O 
Glin Gly Arg Val Ser Lieu. Thir Arg Glin Ala Ser Trp Asp Phe Asp Ser 
65 70 7s 8O 
Tyr Ser Phe Tyr Met Asp Lieu Lys Ala Lieu. Arg Ser Asp Asp Thr Gly 
85 90 95 
Val Tyr Phe Cys Ala Arg Glin Arg Ser Asp Tyr Trp Asp Phe Asp Wall 
1OO 105 11 O 
Trp Gly Ser Gly Thr Glin Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 13 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 13 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1. 5 1O 15 
Asp Thr Val Thir Ile Thr Cys Glin Ala Asn Gly Tyr Lieu. Asn Trp Tyr 
2O 25 3O 
Glin Glin Arg Arg Gly Lys Ala Pro Llys Lieu. Lieu. Ile Tyr Asp Gly Ser 
35 4 O 45 
Llys Lieu. Glu Arg Gly Val Pro Ser Arg Phe Ser Gly Arg Arg Trp Gly 
SO 55 6 O 
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Glin Glu Tyr Asn Lieu. Thir Ile Asn. Asn Lieu. Glin Pro Glu Asp Ile Ala 
65 70 7s 8O 
Thr Tyr Phe Cys Glin Val Tyr Glu Phe Ile Val Pro Gly Thr Arg Lieu. 
85 90 95 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 14 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 14 
Glin Val Glin Lieu. Lieu. Glin Ser Gly Ala Ala Val Thr Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glu Ala Ser Gly Tyr Asn. Ile Arg Asp Tyr 
2O 25 3O 
Phe Ile His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glin Trp Val 
35 4 O 45 
Gly Trp Ile Asin Pro Llys Thr Gly Glin Pro Asn Asn Pro Arg Lieu Phe 
SO 55 6 O 
Glin Gly Arg Val Ser Lieu. Thir Arg His Ala Ser Trp Asp Phe Asp Thr 
65 70 7s 8O 
Phe Ser Phe Tyr Met Asp Lieu Lys Ala Val Arg Ser Asp Asp Thir Ala 
85 90 95 
Val Tyr Phe Cys Ala Arg Glin Arg Ser Asp Tyr Trp Asp Phe Asp Val 
1OO 105 11 O 
Trp Gly Ser Gly Thr Glin Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 15 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 15 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1. 5 1O 15 
Asp Thr Val Thir Ile Thr Cys Glin Ala Asn Gly Tyr Lieu. Asn Trp Tyr 
2O 25 3O 
Glin Glin Arg Arg Gly Lys Ala Pro Llys Lieu. Lieu. Ile Tyr Asp Gly Ser 
35 4 O 45 
Llys Lieu. Glu Arg Gly Val Pro Ser Arg Phe Ser Gly Arg Arg Trp Gly 
SO 55 6 O 
Glin Glu Tyr Asn Lieu. Thir Ile Asn. Asn Lieu. Glin Ala Glu Asp Ile Ala 
65 70 7s 8O 
Thr Tyr Phe Cys Glin Val Tyr Glu Phe Ala Val Pro Gly Thr Arg Lieu. 
85 90 95 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 16 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 16 
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Glin Val Glin Lieu. Lieu. Glin Ser Gly Ala Ala Val Thr Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glu Ala Ser Gly Tyr Asn. Ile Arg Asp Tyr 
2O 25 3O 
Phe Ile His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glin Trp Val 
35 4 O 45 
Gly Trp Ile Asin Pro Llys Thr Gly Glin Pro Asn Asn Pro Arg Glin Phe 
SO 55 6 O 
Glin Gly Arg Val Ser Lieu. Thir Arg His Ala Ser Trp Asp Phe Asp Thr 
65 70 7s 8O 
Phe Ser Phe Tyr Met Asp Lieu Lys Gly Lieu. Arg Ser Asp Asp Thir Ala 
85 90 95 
Ile Tyr Phe Cys Ala Arg Glin Arg Ser Asp Tyr Trp Asp Phe Asp Val 
1OO 105 11 O 
Trp Gly Ser Gly Thr Glin Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 17 
&211s LENGTH: 107 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 17 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Thr Cys Glin Ala Gly Glin Gly Ile Gly Ser Ser 
2O 25 30 
Lieu. Glin Trp Tyr Glin Glin Llys Pro Gly Lys Ala Pro Llys Lieu. Lieu Val 
35 4 O 45 
His Gly Ala Ser Asn Lieu. His Arg Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 6 O 
Ser Gly Phe His Thr Thr Phe Ser Lieu. Thir Ile Ser Gly Lieu. Glin Arg 
65 70 7s 8O 
Asp Asp Phe Ala Thr Tyr Phe Cys Ala Val Lieu. Glu Phe Phe Gly Pro 
85 90 95 
Gly. Thir Lys Val Glu Ile Lys Arg Thr Val Ala 
1OO 105 
<210s, SEQ ID NO 18 
&211s LENGTH: 122 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 18 
Ser Gln His Leu Val Glin Ser Gly Thr Glin Val Lys Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Ile Ser Cys Glin Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 
2O 25 3O 
Val Lieu. His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp Met 
35 4 O 45 
Gly Trp Ile Llys Pro Val Tyr Gly Ala Arg Asn Tyr Ala Arg Arg Phe 
SO 55 6 O 
Glin Gly Arg Ile Asn. Phe Asp Arg Asp Ile Tyr Arg Glu Ile Ala Phe 
65 70 7s 8O 
Met Asp Lieu. Ser Gly Lieu. Arg Ser Asp Asp Thr Ala Lieu. Tyr Phe Cys 
85 90 95 
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Ala Arg Asp Gly Ser Gly Asp Asp Thir Ser Trp His Lieu. Asp Pro Trip 
1OO 105 11 O 
Gly Glin Gly Thr Lieu Val Ile Val Ser Ala 
115 12 O 
<210s, SEQ ID NO 19 
&211s LENGTH: 102 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 19 
Glu Ile Val Lieu. Thr Glin Ser Pro Gly Thr Lieu Ser Leu Ser Pro Gly 
1. 5 1O 15 
Glu Thir Ala Ser Leu Ser Cys Thr Ala Ala Ser Tyr Gly His Met Thr 
2O 25 3O 
Trp Tyr Gln Lys Llys Pro Gly Glin Pro Pro Llys Lieu Lleu. Ile Phe Ala 
35 4 O 45 
Thir Ser Lys Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Glin 
SO 55 6 O 
Phe Gly Lys Glin Tyr Thr Lieu. Thir Ile Thr Arg Met Glu Pro Glu Asp 
65 70 7s 8O 
Phe Ala Arg Tyr Tyr Cys Glin Gln Leu Glu Phe Phe Gly Glin Gly Thr 
85 90 95 
Arg Lieu. Glu Ile Arg Arg 
1OO 
<210 SEQ ID NO 20 
&211s LENGTH: 125 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 2O 
Glin Val Glin Lieu Val Glin Ser Gly Ser Gly Val Llys Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Trp Thr Ser Glu Asp Ile Phe Glu Arg Thr 
2O 25 3O 
Glu Lieu. Ile His Trp Val Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp 
35 4 O 45 
Ile Gly Trp Val Lys Thr Val Thr Gly Ala Val Asn Phe Gly Ser Pro 
SO 55 6 O 
Asp Phe Arg Glin Arg Val Ser Lieu. Thir Arg Asp Arg Asp Lieu. Phe Thr 
65 70 7s 8O 
Ala His Met Asp Ile Arg Gly Lieu. Thr Glin Gly Asp Thr Ala Thr Tyr 
85 90 95 
Phe Cys Ala Arg Gln Lys Phe Tyr Thr Gly Gly Glin Gly Trp Tyr Phe 
1OO 105 11 O 
Asp Lieu. Trp Gly Arg Gly Thr Lieu. Ile Val Val Ser Ser 
115 12 O 125 
<210s, SEQ ID NO 21 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 21 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Thr Cys Glin Ala Ser Arg Gly Ile Gly Lys Asp 
68 
69 
Lieu. Asn Trp Tyr Glin Gln Lys Pro 
35 4 O 
Ser Asp Ala Ser Ile Lieu. Glu Gly 
SO 55 
Ser Gly Phe His Glin Asn Phe Ser 
65 70 
Glu Asp Val Ala Thr Tyr Phe Cys 
85 
Gly. Thir Lys Val Asp Ile Llys 
1OO 
<210s, SEQ ID NO 22 
&211s LENGTH: 131 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 22 
Glin Val Glin Leu Val Glin Ser Gly 
1. 5 
Ser Val Thr Val Ser Cys Llys Phe 
2O 
His Trp Val Asn Pro Ala Pro Glu 
35 4 O 
Ala Pro Gly Glin Gln Lieu. Glu Trp 
SO 55 
Gly Ala Val Asn Tyr Ala Trp Glin 
65 70 
Arg Asp Gly Ser Met Thr Thr Ala 
85 
Ser Asp Asp Thr Ala Val Tyr Tyr 
1OO 
Arg Ser Glu Trp Ala Tyr Ala His 
115 12 O 
Wall Ser Ser 
13 O 
<210s, SEQ ID NO 23 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 23 
Asp Ile Gln Met Thr Glin Ser Pro 
1. 5 
Asp Arg Val Thir Ile Thr Cys Glin 
2O 
Lieu. Asn Trp Tyr Glin Glin Lys Ala 
35 4 O 
Ser Asp Ala Ser Thr Lieu. Glu Gly 
SO 55 
Ser Gly Phe His Glin Asn Phe Ser 
65 70 
Glu Asp Val Ala Thr Tyr Phe Cys 
85 
Gly. Thir Lys Val Asp Ile Llys 
25 
Gly 
Gly 
Luell 
Glin 
Ala 
Ala 
25 
His 
Luell 
Luell 
Phe 
Cys 
105 
Trp 
Ser 
Ala 
25 
Gly 
Gly 
Luell 
Glin 
Wall 
Thir 
Glin 
90 
Ala 
1O 
Glu 
Ala 
His 
Luell 
90 
Ala 
Gly 
Ser 
1O 
Ser 
Wall 
Thir 
Glin 
90 
Ala 
Pro 
Ile 
7s 
Wall 
Asp 
Ile 
Trp 
Gly 
Glu 
Arg 
Glin 
Luell 
Arg 
Ala 
Pro 
Ile 
7s 
Tyr 
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Pro Llys Lieu. Lieu Val 
45 
Ser Arg Phe Ser Gly 
6 O 
Ser Ser Lieu. Glin Pro 
8O 
Glu Thr Phe Gly Glin 
95 
Arg Llys Pro Gly Ala 
15 
Asp Asp Tyr Ser Pro 
3O 
His Phe Lieu. Arg Glin 
45 
Met Asn. Pro Thir Asn 
6 O 
Arg Lieu. Thir Ala Thr 
8O 
Val Arg Ser Lieu. Arg 
95 
Ala Gln Lys Arg Gly 
11 O 
Gly Thr Pro Val Lieu. 
125 
Ser Ala Ser Lieu. Gly 
15 
Gly Ile Gly Lys Asp 
3O 
Pro Llys Lieu. Lieu Val 
45 
Ser Arg Phe Ser Gly 
6 O 
Ser Ser Lieu. Glin Ala 
8O 
Glu Thr Phe Gly Glin 
95 
70 
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<210s, SEQ ID NO 24 
&211s LENGTH: 131 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 24 
Glin Val Glin Lieu Val Glin Ser Gly Ala Ala Val Arg Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Thr Val Ser Cys Llys Phe Ala Glu Asp Asp Asp Tyr Ser Pro 
2O 25 3O 
Tyr Trp Val Asn Pro Ala Pro Glu. His Phe Ile His Phe Lieu. Arg Glin 
35 4 O 45 
Ala Pro Gly Glin Gln Lieu. Glu Trp Leu Ala Trp Met Asn Pro Thr Asn 
SO 55 6 O 
Gly Ala Val Asn Tyr Ala Trp Tyr Lieu. Asn Gly Arg Val Thir Ala Thr 
65 70 7s 8O 
Arg Asp Arg Ser Met Thir Thr Ala Phe Lieu. Glu Wall Lys Ser Lieu. Arg 
85 90 95 
Ser Asp Asp Thir Ala Val Tyr Tyr Cys Ala Arg Ala Gln Lys Arg Gly 
1OO 105 11 O 
Arg Ser Glu Trp Ala Tyr Ala His Trp Gly Glin Gly Thr Pro Val Val 
115 12 O 125 
Wall Ser Ser 
13 O 
<210s, SEQ ID NO 25 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 25 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Thr Cys Glin Ala Ser Arg Gly Ile Gly Lys Asp 
2O 25 3O 
Lieu. Asn Trp Tyr Glin Glin Llys Pro Gly Arg Ala Pro Llys Lieu. Lieu Val 
35 4 O 45 
Ser Asp Ala Ser Ile Lieu. Glu Gly Gly Val Pro Thr Arg Phe Ser Gly 
SO 55 6 O 
Ser Gly Phe His Glin Asn Phe Ser Lieu. Thir Ile Ser Ser Leu Glin Ala 
65 70 7s 8O 
Glu Asp Val Ala Thr Tyr Phe Cys Glin Glin Tyr Glu Thr Phe Gly Glin 
85 90 95 
Gly. Thir Lys Val Asp Ile Llys 
1OO 
<210s, SEQ ID NO 26 
&211s LENGTH: 131 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 26 
Glin Val Glin Lieu Val Glin Ser Gly Ala Ala Val Arg Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Thr Val Ser Cys Llys Phe Ala Glu Asp Asp Asp Phe Ser Pro 
2O 25 3O 
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His Trp Val Asn Pro Ala Pro Glu. His Tyr Ile His Phe Lieu. Arg Glin 
35 4 O 45 
Ala Pro Gly Glin Gln Lieu. Glu Trp Lieu Ala Trp Met Llys Pro Thir Asn 
SO 55 6 O 
Gly Ala Val Asn Tyr Ala Trp Glin Lieu. Glin Gly Arg Val Thr Val Thr 
65 70 7s 8O 
Arg Asp Arg Ser Glin Thir Thr Ala Phe Lieu. Glu Wall Lys Asn Lieu. Arg 
85 90 95 
Ser Asp Asp Thir Ala Val Tyr Tyr Cys Ala Arg Ala Gln Lys Arg Gly 
1OO 105 11 O 
Arg Ser Glu Trp Ala Tyr Ala His Trp Gly Glin Gly Thr Pro Val Val 
115 12 O 125 
Ile Ser Ala 
13 O 
<210s, SEQ ID NO 27 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 27 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Thr Cys Glin Ala Ser Arg Gly Ile Gly Lys Asp 
2O 25 3O 
Lieu. ASn Trp Tyr Glin Gln Lys Arg Gly Arg Ala Pro Arg Lieu. Lieu Val 
35 4 O 45 
Ser Asp Ala Ser Val Lieu. Glu Gly Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 6 O 
Ser Gly Phe His Glin Asn Phe Ser Lieu. Thir Ile Ser Thr Lieu Gln Pro 
65 70 7s 8O 
Glu Asp Val Ala Thr Tyr Phe Cys Glin Glin Tyr Glu Thr Phe Gly Glin 
85 90 95 
Gly. Thir Lys Val Asp Ile Llys 
1OO 
<210s, SEQ ID NO 28 
&211s LENGTH: 131 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 28 
Glin Val Glin Lieu Val Glin Ser Gly Ala Ala Val Arg Llys Pro Gly Ala 
1. 5 1O 15 
Ser Ile Ser Val Ser Cys Llys Phe Ala Asp Ala Asp Asp Tyr Ser Pro 
2O 25 3O 
His Trp Met Asn Pro Ala Pro Glu. His Tyr Ile His Phe Lieu. Arg Glin 
35 4 O 45 
Ala Pro Gly Glin Gln Lieu. Glu Trp Leu Ala Trp Met Asn Pro Thr Asn 
SO 55 6 O 
Gly Ala Val Asn Tyr Ala Trp Tyr Lieu. Asn Gly Arg Val Thir Ala Thr 
65 70 7s 8O 
Arg Asp Arg Ser Met Thir Thr Ala Phe Lieu. Glu Val Arg Ser Lieu. Arg 
85 90 95 
Ser Asp Asp Thir Ala Val Tyr Tyr Cys Ala Arg Ala Gln Lys Arg Ala 
1OO 105 11 O 
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Arg Ser Glu Trp Ala Tyr Ala His Trp Gly Glin Gly Thr Pro Val Val 
115 12 O 125 
Wall Ser Ser 
13 O 
<210s, SEQ ID NO 29 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 29 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Thr Cys Glin Ala Ser Arg Gly Ile Gly Lys Asp 
2O 25 3O 
Lieu. Asn Trp Tyr Glin Glin Lys Ala Gly Lys Ala Pro Llys Lieu. Lieu Val 
35 4 O 45 
Ser Asp Ala Ser Ile Lieu. Glu Gly Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 6 O 
Ser Gly Phe His Glin Asn Phe Ser Lieu. Thir Ile Ser Ser Leu Gln Pro 
65 70 7s 8O 
Glu Asp Val Ala Thr Tyr Phe Cys Glin Glin Tyr Glu Thr Phe Gly Glin 
85 90 95 
Gly. Thir Lys Val Asp Ile Llys 
1OO 
<210s, SEQ ID NO 3 O 
&211s LENGTH: 131 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 30 
Glin Val Glin Lieu Val Glin Ser Gly Ala Ala Val Arg Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Thr Val Ser Cys Llys Phe Ala Glu Asp Asp Asp Trp Ser Pro 
2O 25 3O 
His Trp Val Asn Pro Ala Pro Glu. His Tyr Ile His Phe Lieu. Arg Glin 
35 4 O 45 
Ala Pro Gly Glin Gln Lieu. Glu Trp Leu Ala Trp Met Asn Pro Thr Asn 
SO 55 6 O 
Gly Ala Val Asn Tyr Ala Trp Glin Lieu. Asn Gly Arg Lieu. Thir Ala Thr 
65 70 7s 8O 
Arg Asp Thir Ser Met Thir Thr Ala Phe Lieu. Glu Wall Lys Ser Lieu. Arg 
85 90 95 
Ser Asp Asp Thir Ala Val Tyr Tyr Cys Ala Arg Ala Gln Lys Arg Gly 
1OO 105 11 O 
Arg Ser Glu Trp Ala Tyr Ala His Trp Gly Glin Gly Thr Pro Val Val 
115 12 O 125 
Wall Ser Ser 
13 O 
<210s, SEQ ID NO 31 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 31 
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Glu Ile Val Lieu. Thr Glin Ser Pro Gly Ile Leu Ser Leu Ser Pro Gly 
1. 5 1O 15 
Glu Thir Ala Thr Lieu. Phe Cys Lys Ala Ser Glin Gly Gly Asn Ala Met 
2O 25 3O 
Thir Trp Tyr Glin Lys Arg Arg Gly Glin Val Pro Arg Lieu. Lieu. Ile Tyr 
35 4 O 45 
Asp Thir Ser Arg Arg Ala Ser Gly Val Pro Asp Arg Phe Val Gly Ser 
SO 55 6 O 
Gly Ser Gly Thr Asp Phe Phe Lieu. Thir Ile Asn Llys Lieu. Asp Arg Glu 
65 70 7s 8O 
Asp Phe Ala Val Tyr Tyr Cys Glin Glin Phe Glu Phe Phe Gly Lieu. Gly 
85 90 95 
Ser Glu Lieu. Glu Val His Arg 
1OO 
<210s, SEQ ID NO 32 
&211s LENGTH: 130 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 32 
Glin Val Glin Leu Val Glin Ser Gly Ala Val Ile Llys Thr Pro Gly Ser 
1. 5 1O 15 
Ser Val Lys Ile Ser Cys Arg Ala Ser Gly Tyr Asn. Phe Arg Asp Tyr 
2O 25 3O 
Ser Ile His Trp Val Arg Lieu. Ile Pro Asp Llys Gly Phe Glu Trp Ile 
35 4 O 45 
Gly Trp Ile Llys Pro Lieu. Trp Gly Ala Val Ser Tyr Ala Arg Glin Lieu. 
SO 55 6 O 
Glin Gly Arg Val Ser Met Thr Arg Glin Lieu. Ser Glin Asp Pro Asp Asp 
65 70 7s 8O 
Pro Asp Trp Gly Val Ala Tyr Met Glu Phe Ser Gly Lieu. Thr Pro Ala 
85 90 95 
Asp Thir Ala Glu Tyr Phe Cys Val Arg Arg Gly Ser Cys Asp Tyr Cys 
1OO 105 11 O 
Gly Asp Phe Pro Trp Glin Tyr Trp Gly Glin Gly Thr Val Val Val Val 
115 12 O 125 
Ser Ser 
13 O 
<210s, SEQ ID NO 33 
&211s LENGTH: 104 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 33 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1. 5 1O 15 
Asp Llys Val Thir Ile Thr Cys Glin Thr Ser Ala Gly Tyr Lieu. Asn Trp 
2O 25 3O 
Tyr Glin Glin Arg Arg Gly Arg Ala Pro Llys Lieu Lleu Met Tyr Asp Gly 
35 4 O 45 
Ser Arg Lieu Val Thr Gly Val Pro Ser Arg Phe Ser Gly Arg Arg Trp 
SO 55 6 O 
Gly Thr Glin Tyr Asn Lieu. Thir Ile Gly Ser Leu Gln Pro Glu Asp Ile 
65 70 7s 8O 
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Ala Thr Tyr Tyr Cys Glin Val Tyr Glu Phe Phe Gly Pro Gly Thr Arg 
85 90 95 
Lieu. Asp Lieu Lys Ser Thr Val Ala 
1OO 
<210s, SEQ ID NO 34 
&211s LENGTH: 119 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 34 
Glin Val Glin Lieu Val Glin Ser Gly Thr Ala Val Lys Arg Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glin Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
2O 25 3O 
Phe Ile Tyr Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp Leu 
35 4 O 45 
Gly Trp Ile Asin Pro Leu. Thir Ser Glin Pro Ser Tyr Pro Ser Arg Phe 
SO 55 6 O 
Glin Gly Arg Lieu. Thir Lieu. Thir Arg Asp Thir Phe Asp Glu Met Lieu. Tyr 
65 70 7s 8O 
Met Asp Lieu. Arg Gly Lieu. Arg Ser Asp Asp Thr Gly Ile Tyr Phe Cys 
85 90 95 
Ala Arg Arg His Ser Asp Tyr Cys Asp Phe Asp Ile Trp Gly Ser Gly 
1OO 105 11 O 
Thir Glin Ile Ile Wal Ser Ser 
115 
<210s, SEQ ID NO 35 
&211s LENGTH: 103 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 35 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Arg Val Gly 
1. 5 1O 15 
Asp Thr Val Thir Ile Thr Cys Glin Ala Asn Gly Tyr Lieu. Asn Trp Tyr 
2O 25 3O 
Glin Glin Arg Arg Gly Lys Ala Pro Llys Lieu. Lieu. Ile Tyr Asp Gly Ser 
35 4 O 45 
Llys Lieu. Glu Arg Gly Val Pro Ser Arg Phe Ser Gly Arg Arg Trp Gly 
SO 55 6 O 
Glin Glu Tyr Asn Lieu. Thir Ile Asn. Asn Lieu. Glin Pro Glu Asp Ile Ala 
65 70 7s 8O 
Thr Tyr Phe Cys Glin Val Tyr Glu Phe Ala Val Pro Gly Thr Arg Lieu. 
85 90 95 
Asp Lieu Lys Arg Thr Val Ala 
1OO 
<210s, SEQ ID NO 36 
&211s LENGTH: 123 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 36 
Glin Val Glin Lieu. Lieu. Glin Ser Gly Ala Val Val Thr Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Glu Ala Ser Gly Tyr Lys Ile Arg Asp Tyr 
80 
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2O 25 3O 
Phe Ile His Trp Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glin Trp Val 
35 4 O 45 
Gly Trp Ile Asin Pro Glin Thr Gly Glin Pro Asn Ile Pro Arg Pro Phe 
SO 55 6 O 
Glin Gly Arg Val Thir Lieu. Thir Arg His Ala Ser Trp Asp Phe Asp Thr 
65 70 7s 8O 
Phe Ser Phe Tyr Met Asp Lieu Lys Ala Lieu. Arg Ser Asp Asp Thir Ala 
85 90 95 
Ile Tyr Phe Cys Ala Arg Arg Arg Ser Asp Tyr Cys Asp Phe Asp Val 
1OO 105 11 O 
Trp Gly Ser Gly Thr His Val Thr Val Ser Ser 
115 12 O 
<210s, SEQ ID NO 37 
&211s LENGTH: 107 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OO > SEQUENCE: 37 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly 
1. 5 1O 15 
Asp Arg Val Asn. Ile Thr Cys Glin Ala Ser Arg Asp Thr Gly Ser Ala 
2O 25 3O 
Lieu. Asn Trp Tyr Glin Glin Llys Val Gly Arg Pro Pro Arg Lieu. Lieu. Ile 
35 4 O 45 
Ser Ala Val Ser Asn Lieu. Gly Ala Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 6 O 
Arg Arg Ser Gly Thr Glin Ser Thr Lieu. Thir Ile Asn Thr Lieu. Glin Pro 
65 70 7s 8O 
Glu Asp Ile Ala Thr Tyr Phe Cys Gln His Tyr Glu Phe Phe Gly Pro 
85 90 95 
Gly. Thir Lys Val Asp Ile Lys Arg Thr Val Ala 
1OO 105 
<210s, SEQ ID NO 38 
&211s LENGTH: 125 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 38 
Glu Val Glin Lieu Val Glin Ser Gly Ser Asp Val Arg Llys Pro Gly Ala 
1. 5 1O 15 
Thr Val Thr Val Ser Cys Lys Ala Asp Glu Asp Glu Asp Asp Phe Thr 
2O 25 3O 
Ala Tyr Asn Tyr Phe Met His Trp Val Arg Glin Ala Pro Gly His Gly 
35 4 O 45 
Lieu. Glu Trp Ile Gly Trp Ile Asin Pro Arg Thr Gly Glin Pro Asn His 
SO 55 6 O 
Ala Lys Glin Phe Glin Gly Arg Val Thir Lieu. Thir Arg Glu Arg Ser Thr 
65 70 7s 8O 
Ser Thr Val Phe Met Lys Lieu. Thir Asn Lieu. Arg Lieu. Asp Asp Thir Ala 
85 90 95 
Val Tyr Phe Cys Ala Arg Pro Leu Arg Gly Gly Asp Thir Trp His Tyr 
1OO 105 11 O 
His Ser Trp Gly Arg Gly. Thir Ser Lieu. Thr Val Ser Ser 
115 
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12 O 125 
<210s, SEQ ID NO 39 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
Asp Ile Gln Met 
1. 
Asp 
Ser 
Gly 
65 
Ala 
Lell 
Lys 
Glin 
Arg 
SO 
Thir 
Thir 
Asp 
Wall 
Glin 
35 
Luell 
Glin 
Luell 
Thir 
Arg 
Wall 
Tyr 
Tyr 
Lys 
1OO 
104 
Homo sapiens 
39 
Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
5 1O 15 
Ile Thr Cys Glin Thr Ser Ala Gly Tyr Lieu. Asn Trp 
25 3O 
Arg Gly Arg Ala Pro Llys Lieu Lleu Met Tyr Asp Gly 
4 O 45 
Thr Gly Val Pro Ser Arg Phe Ser Gly Arg Arg Trp 
55 6 O 
Asn Lieu. Thir Ile Gly Ser Lieu Gln Pro Glu Asp Wall 
70 7s 8O 
Cys Glin Val Tyr Glu Phe Phe Gly Pro Gly Thr Arg 
85 90 95 
Arg Thr Val Ala 
<210s, SEQ ID NO 4 O 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
Glin 
1. 
Ser 
Phe 
Gly 
Glin 
65 
Met 
Ala 
Thir 
Wall Glin Lieu. 
Wall 
Ile 
Trp 
SO 
Gly 
Asp 
Arg 
Glin 
Arg 
Tyr 
35 
Ile 
Arg 
Luell 
Arg 
Ile 
115 
Wall 
Trp 
Asn 
Luell 
Arg 
His 
Ile 
119 
Homo sapiens 
4 O 
Val Glin Ser Gly Thr Ala Val Lys Arg Pro Gly Ala 
5 1O 15 
Ser Cys Glin Ala Ser Gly Tyr Thr Phe Ile Asp His 
25 3O 
Trp Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp Lieu. 
4 O 45 
Pro Leu. Thir Ser Glin Pro Ser Tyr Pro Ser Arg Phe 
55 6 O 
Thr Lieu. Thr Arg Asp Thr Phe Asp Glu Met Leu Tyr 
70 7s 8O 
Gly Lieu. Arg Ser Asp Asp Thr Gly Ile Tyr Phe Cys 
85 90 95 
Ser Asp Tyr Cys Asp Phe Asp Ile Trp Gly Ser Gly 
105 11 O 
Wall Ser Ser 
<210s, SEQ ID NO 41 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Homo sapiens 
PRT 
<4 OOs, SEQUENCE: 
122 
41 
Asp Ile Gln Met Thr Glin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Asn. Cys Glin Ala Gly Glin Gly Ile Gly Ser Ser 
25 3O 
Lieu. Asn Trp Tyr Glin Llys Llys Pro Gly Arg Ala Pro Llys Lieu. Lieu Val 
35 4 O 45 
84 
85 
His Gly Ala Ser Asn Lieu. Glin Arg 
SO 55 
Ser Gly Phe His Thr Thr Phe Thr 
65 70 
Asp Asp Wall Ala Thr Tyr Phe Cys 
85 
Gly. Thir Lys Val Asp Ile Lys Arg 
1OO 
Ile Phe Pro Pro Ser Asp Glu Gln 
115 12 O 
<210s, SEQ ID NO 42 
&211s LENGTH: 127 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 42 
Ser Gln His Leu Val Glin Ser Gly 
1. 5 
Ser Val Arg Val Ser Cys Glin Ala 
2O 
Ile Lieu. His Trp Trp Arg Glin Ala 
35 4 O 
Gly Lieu. Ile Llys Pro Val Phe Gly 
SO 55 
Gln Gly Arg Ile Gln Lieu. Thir Arg 
65 70 
Lieu. Asp Lieu. Ser Gly Lieu. Arg Ser 
85 
Ala Arg Asp Glu Ser Gly Asp Asp 
1OO 
Gly Glin Gly Thr Glin Val Ile Val 
115 12 O 
<210s, SEQ ID NO 43 
&211s LENGTH: 101 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 43 
Glu Ilie Wall Lieu. Thir Glin Ser Pro 
1. 5 
Glu Thir Ala Ser Leu Ser Cys Thr 
2O 
Trp Tyr Gln Lys Llys Pro Gly Glin 
35 4 O 
Thir Ser Lys Arg Ala Ser Gly Ile 
SO 55 
Phe Gly Lys Glin Tyr Thr Lieu. Thr 
65 70 
Phe Ala Gly Tyr Tyr Cys Glin Glin 
85 
Arg Lieu. Glu Ile Arg 
1OO 
<210s, SEQ ID NO 44 
Gly 
Luell 
Ala 
Thir 
105 
Luell 
Thir 
Ser 
25 
Pro 
Ala 
Asp 
Asp 
Luell 
105 
Ser 
Gly 
Ala 
25 
Pro 
Pro 
Ile 
Wall 
Wall 
Thir 
Wall 
90 
Wall 
Glin 
Gly 
Gly 
Wall 
Ile 
Asp 
90 
Pro 
Thir 
1O 
Ala 
Pro 
Asp 
Thir 
Glu 
90 
Pro 
Ile 
7s 
Phe 
Ala 
Wall 
Tyr 
Glin 
ASn 
Tyr 
Thir 
Trp 
Ala 
Luell 
Ser 
Arg 
Arg 
7s 
Phe 
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Ser 
6 O 
Ser 
Glin 
Ala 
Thir 
Gly 
Tyr 
6 O 
Arg 
Ala 
His 
Ser 
Ser 
Lell 
Phe 
6 O 
Met 
Phe 
Arg 
Ser 
Trp 
Pro 
Phe 
Lell 
45 
Ala 
Glu 
Wall 
Lell 
Thir 
125 
Lell 
Gly 
Lell 
45 
Ser 
Glu 
Gly 
Phe 
Luell 
Phe 
Ser 
11 O 
Pro 
Thir 
Glu 
Arg 
Ile 
His 
11 O 
Ser 
His 
Ile 
Gly 
Pro 
Glin 
Ser 
Glin 
Gly 
95 
Wall 
Gly 
15 
Asn 
Trp 
Glin 
Ala 
Tyr 
95 
Pro 
Gly 
Pro 
15 
Met 
Phe 
Ser 
Glu 
Gly 
95 
Gly 
Pro 
8O 
Pro 
Phe 
Ala 
Tyr 
Met 
Phe 
Phe 
Cys 
Trp 
Gly 
Thir 
Ala 
Glin 
Asp 
8O 
Thir 
86 
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&211s LENGTH: 125 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 44 
Glin Val Glin Lieu Val Glin Ser Gly Ser Gly Val Llys Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Trp Thr Ser Glu Asp Ile Phe Glu Arg Thr 
2O 25 3O 
Glu Lieu. Ile His Trp Val Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp 
35 4 O 45 
Ile Gly Trp Val Lys Thr Val Thr Gly Ala Val Asn Phe Gly Ser Pro 
SO 55 6 O 
Asn Phe Arg His Arg Val Ser Lieu. Thir Arg Asp Arg Asp Lieu. Phe Thr 
65 70 7s 8O 
Ala His Met Asp Ile Arg Gly Lieu. Thr Glin Gly Asp Thr Ala Thr Tyr 
85 90 95 
Phe Cys Ala Arg Gln Lys Phe Glu Arg Gly Gly Glin Gly Trp Tyr Phe 
1OO 105 11 O 
Asp Lieu. Trp Gly Arg Gly Thr Lieu. Ile Val Val Ser Ser 
115 12 O 125 
<210s, SEQ ID NO 45 
&211s LENGTH: 128 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
< 4 OO SEQUENCE: 45 
Glin Val Glin Leu Val Glin Ser Gly Gly Gly Val Lys Llys Pro Gly Thr 
1. 5 1O 15 
Ser Ala Ser Phe Ser Cys Arg Thir Ser Asp Asp Ile Tyr Asp Asn. Glu 
2O 25 3O 
Phe Phe Asp Ser Ala Phe Met His Trp Val Arg Lieu. Ile Pro Gly Glin 
35 4 O 45 
Arg Pro Glu Trp Met Gly Trp Met Asn Pro Arg Ser Gly Ala Val Asn 
SO 55 6 O 
Tyr Ala Arg Glin Lieu. Glin Pro Arg Val Ser Met Tyr Arg Asp Arg Asp 
65 70 7s 8O 
Lieu. Ser Thr Ala Tyr Met Glu Phe Llys Ser Lieu. Thir Ser Ala Asp Thr 
85 90 95 
Gly. Thir Tyr Phe Cys Ala Arg Llys Lys Arg Gly Asp Gly Phe Asn Lieu. 
1OO 105 11 O 
Tyr Phe Asp Lieu. Trp Gly Arg Gly Ser Glin Val Ile Val Ser Ser Ala 
115 12 O 125 
<210s, SEQ ID NO 46 
&211s LENGTH: 126 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 46 
Glin Val Glin Lieu Val Glin Ser Gly Ser Ala Met Lys Llys Pro Gly Ala 
1. 5 1O 15 
Ser Val Arg Val Ser Cys Trp Thr Ser Glu Asp Ile Phe Asp Thir Thr 
2O 25 3O 
Glu Lieu. Ile His Trp Val Arg Glin Ala Pro Gly Glin Gly Lieu. Glu Trp 
35 4 O 45 
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Ile Wall Ala Wall 
55 
Gly Ala Wall 
SO 
Asn 
6 O 
Trp Lys Ser Gly 
Phe Wall 
70 
Asp His Ser Lieu. Thir 
65 
Arg Arg Arg Asp Arg Asp 
Ala Met Ile 
85 
Thr Gin 
90 
His Asp Arg Gly Lieu. Asp Asp Thr 
Phe Cys Ala Arg Glin Phe Ala Glin Lys Arg 
105 
Gly Asp Gly 
Thir Ile Wal Wall Ser 
125 
Luell Ser 
12 O 
Asp Lieu. Trp 
115 
Gly Arg Gly 
What is claimed is: 
1. A human anti-CD4 binding site (anti-CD4bs) antibody 
having a heavy chain and a light chain, 
the heavy chain comprising 
a Substitution at position 54 according to Kabat num 
bering, the substitution being selected from the 
group consisting of alanine, isoleucine, leucine, 
methionine, phenylalanine, tryptophan, tyrosine, 
Valine, histidine, arginine, glutamine, asparagine, 
lysine, glutamic acid, and aspartic acid, the heavy 
chain comprising a sequence selected from the group 
consisting of SEQID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 
45, and 46; and 
the light chain comprising a sequence selected from the 
group consisting of SEQID NOs: 1, 3, 5, 7, 9, 11, 13, 
15, 17, 19, 21, 23, 25, 27, 29, 31, 33,35, 37, 39, 41, and 
43. 
2. The human anti-CD4bs antibody of claim 1, wherein 
the heavy chain Substitution is tryptophan, tyrosine, phenyl 
alanine, histidine, arginine, glutamine, or asparagine. 
3. The human anti-CD4bs antibody of claim 1, wherein 
the human anti-CD4bs antibody is selected from the group 
consisting of VRC01, VRC02, NIH-45-46, 3BNC60, 
Tyr Gly Ser 
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3BNC117, 3BNC62, 3BNC95, 3BNC176, 12A21, VRC 
PG04, VRC-CH30, VRC-CH31, VRC-CH32, VRC-CH33, 
VRC-CH34, VRC03 heavy chain with VRC01 light chain, 
gVRC-H5(d74) heavy chain with VRC-PG04 light chain, 
gVRC-H12(d74) heavy chain with VRC-PG04 light chain, 
VRC03, VRC01 heavy chain with VRC03 light chain, 
3BNC55, 3BNC91, 3BNC104,3BNC89, 12A21, and VRC 
PGO4b. 
4. The human anti-CD4bs antibody of claim 3, wherein 
the heavy chain Substitution is phenylalanine, tryptophan, 
tyrosine, histidine, arginine, glutamine or asparagine. 
5. The human anti-CD4bs antibody of claim 1, wherein 
the human anti-CD4bs antibody is NIH45-46. 
6. The human anti-CD4bs antibody of claim 5, wherein 
the heavy chain Substitution is phenylalanine, tryptophan, 
tyrosine, histidine, arginine, glutamine or asparagine. 
7. A pharmaceutical composition comprising the human 
anti-CD4bs antibody of claim 1 or a fragment thereof, and 
a pharmaceutically acceptable carrier. 
8. The human anti-CD4bs antibody of claim 1, wherein 
the light chain comprises a Substitution of tyrosine at posi 
tion 28 according to Kabat numbering. 
k k k k k 
